 
 
PEGCETACOPLAN (APL -2) 
PROTOCOL APL2-304 
A PHASE 3, MULTICENTER, RANDOMIZED, 
DOUBLE -MASKED, SHAM -CONTROLLED STUDY TO 
COMPARE THE EFFICACY AND SAFETY OF 
INTRAVITREAL PEGCETACOPLAN THERAPY WITH 
SHAM INJECTIONS IN PATIENTS WITH 
GEOGRAPHIC ATROPHY (GA) SECONDARY TO 
AGE -RELATED MACULAR DEGENERATION (AMD)  
 
US IND No. : 124784  
EudraCT No.:  2018-001435-52 
Phase: 3 
Version:  Amendment 5 
Date:  12 August 2020  
Confidentiality Statement 
This document is confidential. It contains proprietary information of Apellis Phar maceutical s, 
Inc. Any viewing or disclosure of such information that is not authorized in writing by Apellis 
Pharmaceutical s, Inc, is strictly prohibited. Such information may be used solely for the purpose 
of reviewing or performing this study. 
 
 
Apellis Pharmaceuticals, Inc
Page 1 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
INVESTIGAT OR AGREEMENT  
Long Title :  A Phase 3, Multi-Center, Randomized, Double-
Masked, Sham-Controlled Study to Compare the 
Efficacy and Safety of Intravitreal Pegcetacoplan  
Therapy with Sham Injections in Patients with 
Geographic Atrophy (GA) Secondary to Age-
Related Macular Degeneration (AMD)  
Short  Title :  Oaks  
Protocol Number , Version,  and Date : APL2 -304 / Amendment 5 / 12 August 2020  
Study  Phase :  Phase 3  
Sponsor  Name  and Address :  Apellis Pharmaceuticals, Inc  
 100 5th  Ave  
 Waltham, MA 02451 
 USA  
Investigational Test  Article:  Pegcetacoplan  intravitreal injection  (also known as 
APL -2) 
US IND Number:  124784 
E
udra
CT Number:  2018-001435-52  
Indication Studied: Geographic atrophy secondary to age- related 
macular degeneration  
Investigator Agreement : I have read  the clinical  study described  herein , 
recognize its  confidentiality , and  agree to  conduct 
the described  trial in compliance with  Good Clinical 
Practice ( GCP ), the ethical  principles contained  
within  the Declaration  of Helsinki, this  protocol, 
and all applicable regulatory requirements .  
 
 Principal  Investigator :  
 Name: ____________________________________ 
  Signature : _________________________________  
 
 Date: ______/______/______ ( DD/MMM/ YYYY ) 
 
 
 
Apellis Pharmaceuticals, Inc
Page 2 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
PROTOCOL AMENDMENT SUMMARY OF CHANGES  
Amendment 5: Summary of Changes From the Previous Version  
Amendment Date: 12 August 2020 Updates to the protocol implemented in th is amendment are provided in the table below.  
Description of change  Section(s) affected by change 
Nonsubstantial changes that did not impact content of the document have 
been made for clarity.  Entire document  
Updated company address  Investigator Agreement and Sponsor Information  
Changed APL -2 to International Nonproprietary Name : pegcetacoplan, 
updated related abbreviations and protocol title  Entire document  
Added the descriptor “maximum” when referencing reading speed Synops is, Section  5.1.2, 
Section  5.1.5, Section  12.7.2, 
Section  12.7.3  
Removed the 6 -month follow -up period and updated the study length 
from 30 mon ths to 24 months and made it a 30- or 60- day follow -up 
period based on treatment group because that length of time is deemed 
sufficient to evaluate the safety of pegcetacoplan based on its half -life in 
the vitreous. Additionally, there is an option for subjects to enroll in a separate extension study ( Study  APL2 -GA-305) during which longer -
term safety and efficacy will be collected.  Synopsis , Section  8, 
Section  8.1.3.2.1 , Section  11.8 
Inclusion criterion  6c was updated from “ Reliability test ratio must be 
≤20%” to “Fixation losses must be ≤20% ” on the basis of regulatory 
feedback  provided to the microperimetry device manuf acturer  Synopsis , Section  6.1.1  
Updated the text regarding the sample size to both simplify and reduce redundancies  Synopsis , Section  12.5 
Previous Section  4.1.3.1 , Pharmacokinetics , moved to Section  4.1.3.2 to 
follow Section  4.1.3.1 , Toxicology  Section  4.1.3.1, Section  4.1.3.2  
Updated the formulation information  Section  4.1.2, Section  7.3.3.1  
Revised number of injections for each treatment arm because the 
injections at Month 24 will no longer be administered Section  7.3.1 ( Table 1 ), Section  8 
Updated the text regarding endophthalmitis for clarity  Section  7.5.3  
Updated Study Schema  Section  8 
Revised Study Procedures based on the removal of the M onth 24 
injection and the 6- month follow -up period  Section  8 
Revised the language reg arding genotyping samples to indicate that these 
samples will be collected only for sub jects who consent to the analysis  Section  9.7 
Updated the language within the Adverse Events definition section to be consistent with the new Apellis standard language  Section  11.1 
Updated the language within the Recording Adverse Events section to be consistent with the new Apellis standard language  Section  11.2 
 
 
Apellis Pharmaceuticals, Inc
Page 4 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Removed the section on Treatment and F ol low-up of Adverse Events 
because the information contained within it is now included in other 
revised sections to align with new Apellis standard language  Section  11.3 
Updated the language within the Reporting Adverse Events section to be 
consistent with the new Apellis standard language  Section  11.3 
Updated the language within the Serious Adverse Events section to be 
consistent with the new Apellis standard language  Section  11.4 
Removed the section on Unexpected Adverse Events or Unexpected Suspected Adverse Reactions because the information contained within it is now included in other revised sections to align with new Apellis standard language  previous ly Section  11.6 
Updated the language within the Pregnancy section to be consistent with the new Apellis standard language  Section  11.6 
Removed APL -2 investigator’s brochure  from references  Section  15 
Updated Footnote G  and M  Appendix A , Appendix B , 
Appendix C , Appendix D , and 
Appendix K  
Deleted follow -up visits from Schedules of Activities  Appendi x B and Appendix D , and 
Table B and Table  D of Appendix K  
Deleted pegcetacoplan and sham administration  and post injection  
assessment from Visit 2 0 of the Schedule of Activities for monthly and 
every-other-month treatment groups Month 13 to Month 24 Appendix B  and Appendix D  and 
Tables B and D of Appendix  K 
 
 
Apellis Pharmaceuticals, Inc
Page 5 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
1. TABLE OF CONTENTS  
 
INVESTIGATOR AGREEMENT ...................................................................................................2  
SPONSOR INFORMATION  ..........................................................................................................3  
PROTOCOL AMENDMENT SUMMARY OF CHANGES  ..........................................................4  
1. TABLE OF CONTENTS  .............................................................................................6  
LIST OF TABLES  .........................................................................................................................11  
LIST OF FIGURES  .......................................................................................................................11  
2. SYNOPSIS  .................................................................................................................12  
3. ABBREVIATIONS  ....................................................................................................20  
4. INTRODUCTION  ......................................................................................................23  
4.1. Background .................................................................................................................23  
4.1.1.  Age-Related Macular Degeneration  .....................................................................23  
4.1.2.  Pegcetacoplan  .......................................................................................................23  
4.1.3.  Nonclinical Data  ...................................................................................................24  
  
  
4.1.4.  Clinical Data  .........................................................................................................27  
4.1.5.  Rationale  ...............................................................................................................28  
4.1.5.1.  Rationale for Pegcetacoplan for  Treatment of Geographic 
Atrophy .....................................................................................................28  
4.1.6.  Dose Selection  ......................................................................................................28  
4.2. Risk/Benefit ................................................................................................................28  
5. STUDY OBJECTIVES  ..............................................................................................30  
5.1.1.  Primary Objective  .................................................................................................30  
5.1.2.  Key Secondary Objectives ....................................................................................30  
5.1.3.  Secondary Objectives  ...........................................................................................30  
5.1.4.  Safety Objectives  ..................................................................................................30  
5.1.5.  Exploratory Objectives .........................................................................................31  
6. PATIENT POPULATION ..........................................................................................32  
6.1.1.  Inclusion Criteria  ..................................................................................................32  
 
 
Apellis Pharmaceuticals, Inc
Page 6 of 164
Confidential
CCI
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
6.1.2.  Exclusion Criteria  .................................................................................................33  
6.2. Women of Childbearin g Potential  ..............................................................................34  
6.3. Women of Nonchildbearing Potential ........................................................................34  
6.4. Approved Methods of Contraception .........................................................................34  
6.5. Discontinuation of Subjects ........................................................................................35  
7. TREATMENT OF SUBJECTS  ..................................................................................36  
7.1. Allocation to Treatment  ..............................................................................................36  
7.2. Masking and Minimizatio n of Bias ............................................................................36  
7.2.1.  Unmasking ............................................................................................................37  
7.3. Dosage and Administration ........................................................................................37  
7.3.1.  Dose Levels and Treatment Arms  ........................................................................37  
7.3.2.  Treatment Ad ministration  .....................................................................................37  
7.3.3.  Drug Supplies .......................................................................................................38  
7.3.3.1.  Identity of Investigational Product ...........................................................38  
7.3.3.2.  Storage ......................................................................................................38  
7.3.3.3.  Accountability  ...........................................................................................38  
7.3.4.  Intravitreal Pegcetacoplan Administration  ...........................................................39  
7.4. Sham Injection Administration  ...................................................................................39  
7.5. Concomitant Therapies ...............................................................................................39  
7.5.1.  Treatment of New Exudation Related to Active Choroidal 
Neovascularization in the Study Eye and/or Fellow Eye ...............................39  
7.5.2.  Prohibited Therapies .............................................................................................40  
7.5.3.  Endophthalmitis Treatment ..................................................................................40  
8. STUDY PROCEDURES  ............................................................................................42  
8.1. Study Visit Schedule ...................................................................................................43  
8.1.1.  Screening Period —Within 28 Days Prior to Randomization/ Treatment 
(Day –28 to –1) ...............................................................................................43  
8.1.1.1.  Visit 1—All Subjects  ................................................................................43  
8.1.2.  Randomization/ Initial Treatment—Day  1—Within 28 Days of 
Screening  ........................................................................................................44  
8.1.2.1.  Visit 2—All Groups ..................................................................................44  
8.1.3.  Treatment Phase—24 Months ..............................................................................44  
8.1.3.1.  Months 1-12 ..............................................................................................44  
 
 
Apellis Pharmaceuticals, Inc
Page 7 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
8.1.3.2.  Months 13-24 ............................................................................................45  
8.1.4.  Early Termination Visit ........................................................................................46  
8.1.5.  Unscheduled Visits ...............................................................................................46  
9. ASSESSMENTS .........................................................................................................47  
9.1. Informed Consent .......................................................................................................47  
9.2. Demographic Information/ Medical/ Surgical History  ...............................................47  
9.3. Ocular History/ Ocular Procedures  .............................................................................47  
9.4. Vital Signs  ..................................................................................................................47  
9.5. Physical Examination  .................................................................................................47  
9.6. Laboratory Analysis of Blood and Urine ....................................................................47  
9.7. Genotyping Samples ...................................................................................................48  
9.8. Urine Pregnancy Test  .................................................................................................48  
9.9. Patient -Reported Outcomes  ........................................................................................49  
9.9.1.  The National Eye Institute Visual Functioning Questionnaire 25- Item 
Version (NEI- VFQ)  ........................................................................................49  
9.9.2.  The Functional Reading Independence (FRI) Index ............................................49  
9.10.  Best Corrected Visual Acuity and Low Luminance Best Corrected Visual 
Acuity  ...................................................................................................................49  
9.11.  Minnesota Low-Vision Reading (MNREAD) Test or Radner Reading Charts 
(in select countries)  ...............................................................................................50  
9.12.  Home -Based Functional Digital Applications (optional, select sites)  ........................50  
9.13.  Complete Ophthalmic Exam .......................................................................................50  
9.14.  Ocular Imaging and M icroperimetry  ..........................................................................50  
9.15.  Postinjection Assessment............................................................................................51  
9.16.  Blood Volume for Study Assessments .......................................................................52  
9.17.  Samples for Clinical Repository (Optional, Select Sites)  ...........................................52  
9.17.1.  Approval by the Institutional Review Board or Ethics Committee ................53  
9.17.2.  Sample Collection  ...........................................................................................53  
9.17.3.  Confidentiality and Data Ownership ..............................................................53  
9.17.4.  Consent to Participate in the Clinical Repository  ...........................................54  
9.17.5.  Withdrawal From the Clinical Repository  ......................................................54  
9.17.6.  Monitoring and Oversight...............................................................................54  
10. SAFETY EVALUATIONS  ........................................................................................55  
 
 
Apellis Pharmaceuticals, Inc
Page 8 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
10.1.  Data Monitoring Committee  .......................................................................................55  
11. ADVERSE EVENTS ..................................................................................................56  
11.1.  Definition  ....................................................................................................................56  
11.2.  Recording Adverse Events .........................................................................................56  
11.3.  Reporting Adverse Events ..........................................................................................57  
11.3.1.  Relationship of Events to Study Treatment ....................................................57  
11.3.2.  Severity of Events ...........................................................................................57  
11.4.  Serious Adverse Events ..............................................................................................58  
11.5.  Treatment and Follow-up of Adverse Events .............................................................58  
11.6.  Pregnancy  ...................................................................................................................59  
11.7.  Disease Progression  ....................................................................................................59  
11.8.  Withdrawal  .................................................................................................................59  
12. DATA MANAGEMENT AND STATISTICAL CONSIDERATIONS  ....................60  
12.1.  Data Collection  ...........................................................................................................60  
12.2.  Clinical Data Management  .........................................................................................60  
12.3.  Statistical Analysis Process  ........................................................................................60  
12.4.  Planned Interim Analysis and Data Safety Monitoring Committee ...........................60  
12.5.  Sample Size Calculation and Power Considerations  ..................................................61  
12.6.  Statistical Analysis Sets  ..............................................................................................61  
12.7.  Efficacy Analyses  .......................................................................................................62  
12.7.1.  Primary Efficacy Analysis  ..............................................................................62  
12.7.2.  Secondary Efficacy Analysis ..........................................................................63  
12.7.3.  Exploratory Efficacy Analysis ........................................................................64  
12.8.  Safety Analyses  ..........................................................................................................64  
12.8.1.  Anti-Therapeutic Antibodies ..........................................................................65  
12.8.2.  Death  ...............................................................................................................65  
12.8.3.  Ocular Assessments  ........................................................................................65  
12.9.  Handling of Missing Data ...........................................................................................65  
12.10.  Visit Windows  ............................................................................................................65  
13. ETHICS  ......................................................................................................................66  
13.1.  Ethical Conduct of the Study ......................................................................................66  
13.2.  Institutional Review Board/Ethic Committee  .............................................................66  
13.3.  Subject Information and Consent ...............................................................................66  
 
 
Apellis Pharmaceuticals, Inc
Page 9 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
14. ADMINISTRATIVE CONSIDERATIONS  ..............................................................67  
14.1.  Direct Access to Source Data/Documents  ..................................................................67  
14.2.  Quality Control and Quality Assurance ......................................................................67  
14.3.  Monitoring ..................................................................................................................67  
14.4.  Data Handling and Record Keeping ...........................................................................67  
14.5.  Protocol Amendments ................................................................................................68  
14.6.  Report Format .............................................................................................................68  
14.7.  Finance and Insurance ................................................................................................68  
14.8.  Publication Policy  .......................................................................................................68  
14.9.  ClinicalTrials .gov .......................................................................................................69  
14.10.  Termination of Study ..................................................................................................69  
15. REFERENCES  ...........................................................................................................70  
16. APPENDICES  ............................................................................................................72  
APPENDIX A: VISIT SCHEDULE —Monthly Group—Screening, Day  1 through 
Month 12 ...............................................................................................................72  
APPENDIX B: VISIT SCHEDULE —Monthly Group—Month 13 to Month 24 ..................75  
APPENDIX C: VISIT SCHEDULE —Every -Other -Month Group—Screening, Day 1 
Through Month 12 ................................................................................................78  
APPENDIX D: VISIT SCHEDULE —Every -Other -Month Group—Month 13 to 
Month 24 ...............................................................................................................81  
APPENDIX E: NATIONAL EYE INSTITUTE VISUAL FUNCTIONING 
QUESTIONNAIRE 25 -ITEM VERSION  ............................................................84  
APPENDIX F: FUNCTIONAL READING INDEPENDENCE INDEX (FRI)  ...................101  
APPENDIX G: MINNESOTA LOW -VISION READING TEST (MNREAD) AND 
RADNER READING CARDS ...........................................................................102  
APPENDIX H: GRADING SCALE FOR ASSESSMENT OF ANTERIOR  
CHAMBER FLARE OR CELLS  .......................................................................103  
APPENDIX I: GRADING SCALE FOR ASSESSMENT OF VITREOUS CELLS  ............105  
APPENDIX J: AMENDMENT HISTORY  ...........................................................................106  
APPENDIX K: PROTOCOL CHANGES TO BE FOLLOWED DURING COVID-
19 RESTRICTIONS  ...........................................................................................118  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 10 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
LIST OF TABLES  
Table 1:  Treatment Arms with Approximate Number of Subjects ...............................................37  
Table 2:  Laboratory Sampling and Analysis ................................................................................48  
Table 3:  Total Study Blood Volume .............................................................................................52  
Table 4:  Power to Detect a Difference Among 3 Groups With an Equal Size of 
200 Subjects  ................................................................................................................61  
 
LIST OF FIGURES  
Figure 1:  Study Schema ................................................................................................................42  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 11 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
2. SYNOPSIS  
Study Title  
A Phase 3 , Multic enter, Randomized, Double -Masked, Sham -Controlled Study to Compare the Efficacy and Safety 
of Intravitreal P egcetacoplan  Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary 
to Age -Related Macular Degeneration (AMD)  
Protocol Number, Version , and  Date  
APL 2-304/ Amendment 5/ 12 August 2020  
Investi gational Product, Dose , and Route of Administration  
• Pegcetacoplan  (also known as APL -2) 
• 15 mg/0.1 mL 
• Intravitreal (IVT) Injection  
Study Arms  
Arm  Abbreviation  Randomization 
Pegcetacoplan 1 5 mg/0.1 mL monthly for 24 months  PM 2 
Pegcetacoplan 1 5 mg/0.1 mL every other month for 24 months  PEOM  2 
Sham monthly for 24 months  SM 1 
Sham every  other  month for 24 months  SEOM  1 
Study Phase and Type  
Phase 3, multicenter, randomized, double -masked, sham -injection controlled  
Number of Subjects and Sites  
• Approximately 60 0 subject s 
• Approximately 100 sites  
Objectives  
Primary   
To evaluate the efficacy of pegcetacoplan  compared to sham injection in patients with GA secondary to AMD 
assessed by change in the total area of GA lesions from baseline as measured by FAF.  
Key Secondary  
To evaluate the efficacy of pegcetacoplan  compared to sham  injection in patients with GA secondary to AMD with 
respect to:  
• Monocular maximum reading speed (study eye), as assessed by Minnesota Low -Vision Reading Test  
(MNREAD) or Radner Reading Char ts (in select countries)  
• Functional Reading Independence (FRI) index score  
• Normal luminance best  corrected visual acuity score (NL- BCVA) in the study eye  
 
 
Apellis Pharmaceuticals, Inc
Page 12 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Secondary:  
• To evaluate the efficacy of pegcetacoplan  compared to sham  injection in patients with GA s econdary 
to AMD with respect to : 
o Low luminance best corrected visual acuity score (LL -BCVA) in the study eye  
o Low luminance deficit (LLD) in the study eye  
o Total area of GA lesion(s) in the study eye  
o Monocular critical print s ize (study eye), as assessed by  MNREAD or Radner Reading Charts 
(in select countries)   
o National Eye Institute Visual Functioning Questionnaire 2 5 Item Version (NEI VFQ -25) 
distance activity subscale score (in select countries)  
o Macular functional response as assessed by mesopic microperi metry  
Safety:  
• To evaluate the safety and tolerability of pegcetacoplan  compared to sham  injection in patients with 
GA secondary to AMD as indicated by:  
o Incidence and severity of ocular and systemic treatment -emergent adverse events  
o Incidence of anti -thera peutic antibodies directed against pegcetacoplan  
o Incidence of new active CNV in the study eye  
Exploratory  
• To evaluate the efficacy of pegcetacoplan  compared to sham  injection in patients with GA seco ndary 
to AMD as indicated by:  
o NEI VFQ- 25 composite score  
o NEI VFQ- 25 near activity subscale score (in select countries)  
o Comparison between study eye and fellow eye in change in GA lesion size  
o To evaluate the binocular maximum reading speed as assessed by MNREAD or Radner 
Reading Charts (in select countries)  
o To evaluate the binocular critical print size as assessed by MNREAD or Radner Reading 
Charts (in select countries)  
• To evaluate the r elationship between genetic polymorphisms associated with AMD with GA 
progression and response to pegcetacoplan  
• To evaluate the i ncidence of new onset of subclinical CNV in the study eye  
• To assess sensitivity and specificity of a digital reading speed application to detect disease progression 
/ regression  (optional, select sites)  
• To assess sensitivity and specificity of a digital visual function application to detect disease 
progression / regression (optional, select sites)  
 
 
Apellis Pharmaceuticals, Inc
Page 13 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Inclusion Criteria  
The study e y
e must meet all inclusion criteria . If both eyes meet the inclusion criteria, the eye with the worst visual 
acuity at the screen ing visit will be designated as the study eye . If both eyes have the same visual acuity, the right 
eye will be selected as the study eye.  
Ocular -specific inclusion criteria apply to the study eye  only, unless otherwise specified.  
1. Age ≥60 years. 
2. Normal Lumi nance best corrected visual acuity of 24 letters or better using Early Treatment Diabetic 
Retinopathy Study (ETDRS) charts (approximately 20/320 Snellen equivalent).  
3. Clinical diagnosis of GA of the macula secondary to AMD as determined by the investigator and confirmed 
by the r eading center.  
4. The GA lesion must meet the following criteria as determined by the central reading center’s assessment of 
fundus autofluorescence (FAF) imaging at screening:  
a. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas [DA] respectively)  
b. If GA is multifocal, at least 1 focal lesion must be ≥1.25  mm2 (0.5 DA), with the overall aggregate area 
of GA as specified above in  4a. 
c. The entire GA lesion must be completely  visualized on the macula centered image and must be able to 
be imaged in its entirety and not contiguous with any areas of peripapillary atrophy.  
d. Presence of any pattern of hyperautofluorescence in the junctiona l zone of GA. Absence of 
hyperautofluorescence (ie, pattern  = none) is exclusionary.1 
5. Adequate clarity of ocular media, adequate pupillary dilation , and fixation to permit the collection of good 
quality images as determined by the i nvestigator.  
6. Meets the following criteria related to microperimetry:  
a. Able to detect fixation target.  
b. Total elapsed time to complete the 10 -2 68-point  exam is ≤3 0 minutes  in duration .  
c. Fixation losses  must be ≤20% .  
d. Subject is willing and able to undertake microperimetry assessment in the opinion of the investigator .  
7. Female subjects must be:  
a. Women of non– child bearing  potential (WONCBP), or  
b. Women of child bearing  potential (WOCBP) with a negative serum pregnancy test at screening and 
must agree to use protocol defined methods of contraception for the duration of the study and refrain 
from breastfeeding for the duration of the study.  
8. Males with female partners of child bearing  potential must agree to use protocol defined methods of 
contraception and agree to refrain from donating sperm for the duration of the study.  
9. Willing and able to give informed consent and to comply with the study procedures and assessments.  
Exclusion Criteria  
Ocular specific exclusion criteria apply to the study eye  only, unless otherwise specified.  
1. GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy, or  toxic 
maculopathies like plaquenil maculopathy in either eye.  
 
 
Apellis Pharmaceuticals, Inc
Page 14 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
2. Spherical equivalent of the refractive error demonstrating >  6 diopters  o f myopia or an axial length 
>26 mm. 
3. Any history or active choroidal neovascularization (CNV), associated with AMD or any other cause, 
including any evidence of retinal pigment epithelium rips or evidence of neovascularization anywhere 
based on SD -OCT imaging and/or fluorescein angiography as  assessed by the r eading center. 
4. Presence of an active ocular disease that in the opinion of the investigator compromises or confounds visual 
function, including but not limited to, uveitis, other macular diseases (eg,  clinically significant epiretinal 
mem brane [ERM], full thickness macular hole or uncontrolled glaucoma/ocular hypertension). Benign 
conditions in the opinion of the investigator such as peripheral retina dystrophy are not exclusionary.  
5. Intraocular surgery (including lens replacement surgery) wi thin 3 months prior to randomization.  
6. History of laser therapy in the macular region.  
7. Aphakia or absence of the posterior capsule. Note: YAG laser posterior capsulotomy for posterior capsule 
opacification done at least 60 days prior to screening is not exclusionary. 
8. Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention 
during the study period or, in the opinion of the i nvestigator, could compromise visual function during the 
study period.  
9. Any contraindicati on to IVT injection including current ocular or periocular infection.  
10. History of prior intravitreal injection.  
11. Unable to perform microperimetry reliably in the opinion of the investigator.  
12. Prior participation in another interventional clinical study for i ntravitreal therapies  in either eye (including 
subjects receiving sham).  
13. Prior participation in another interventional clinical study for geographic atrophy in either eye including 
investigational oral medication and placebo.  
14. Participation in any systemic  experimental treatment or any other systemic investigational new drug within 
6 week s or 5 half -lives of the active ingredient (whichever is longer) prior to the start of study treatment. 
Note: clinical trials solely involving observation, over -the-counter  vitamins, supplements, or diets are not 
exclusionary.  
15. Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow -up over 
the 24- month treatment period unlikely, or would make the subject an unsafe study candidate.  
16. Any screening laboratory value (hematology, serum chemistry or urinalysis) that in the opinion of the 
investigator is clinically significant and not suitable for study participation.  
17. Known hypersensitivity to fluorescein sodium for injection or hypersensitiv ity to pegcetacoplan or any of 
the excipients in pegcetacoplan solution.  
Study Design  
This is a 24- month, Phase 3 , multicenter, randomized, double -masked, sham -injection  controlled study to assess the 
efficacy and safety of multiple IVT injec tions of pegc etacoplan  in subjects with GA secondary to AMD.  
The study will randomize approximately 600 subject s across approximately 100 multinational sites . Subjects will be 
screened within 28 days before receiving pegcetacoplan  or sham injection . Upon entry into the  study, subjects will 
be assigned a screening number . Subjects who meet all inclusion and none of the exclusion criteria will return to the 
clinic for randomization and treatment on Visit 2 ( Day 1). At this visit, subjects will be randomized 2:2:1:1 to 
 
 
Apellis Pharmaceuticals, Inc
Page 15 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
receive pegcetacoplan monthly, pegcetacopl a n every other month, sham injection monthly, or  sham  injection every  
other  month , respectively . Randomization will be stratified according to GA lesion area at screening (< 7. 5 mm2; ≥ 
7.5 mm2), and presence of CNV in the fellow eye.  
All subjects will be assessed monthly during the first 12 months regardless of treatment regimen. From Month 12 to 
Month 24, subjects will follow the outlined visit schedule ( Appendix A  to Appendix D ) based on treatment 
assignment ( ie, subjects in the monthly groups will be assessed monthly while subjects in the every -other -month  
[EOM] groups will be assessed every  other  month) . The last visit in the study will be at Month 24, approximately 30 
days (monthly treatment group ) or 60 days (EOM treatment group) after the last visit at which investigational 
product is administered.  A t the end of the 24 -month study  period , subjects will have the option to enroll into a 
separate open -label study.  
Subjects who discontinue study treatment can continue participation in the study and should be encouraged to return 
to the clinical site for as many follow -up visits as they can (with the exception of pegcetacoplan /sham 
administration) . Subjects who wish to fully withdraw from the study before Month 24, should be encouraged to 
complete the early termination visit. 
Endpoints and statistical analysis:  
Endpoints  
Primary Efficacy Endpoint  
• Change from baseline to Month 12 in total area of GA lesion(s) in the study eye (in mm2) based on 
fundus autofluorescence ( FAF) .  
Key Secondary Efficacy Endpoints  
• Change from baseline in m onocular maximum reading speed (study eye), as assessed by MNREAD or 
Radner Reading Charts at Month 24 (in select countries)  
• Change from baseline in Functional Reading Independence (FRI) i ndex score, at Month 24.  
• Change from baseline in normal luminance best  corrected visual acuity score (NL- BCVA) at Month 24 
as assessed by ETDRS chart .  
Secondary Efficacy Endpoints  
• Change from baseline in low luminance best corrected visual acuity score (LL -BCVA) at Month 12 
and Month 24 as assessed by ETDRS chart .  
• Change from baseline in low luminance deficit (LLD) at Month 12 and Month 24.  
• Change from baseline at each planned assessment in the total area of GA lesion(s) in  the study eye (in 
mm2) as assessed by FAF . 
• Change from baseline in monocular critical print size (study eye), as assessed by MNREAD  or Radner 
Reading Charts, at Month 12 and Month 24 (in select countries).  
• Change from baseline in the National Eye Institu te Visual Functioning Questionnaire 25- Item Version 
(NEI VFQ -25) distance activity subscale score at Month 12 and Month 24  (in select sites).  
• Number of scotomatous points assessed by mesopic microperimetry for the evaluation of the macular 
functional response .  
 
 
Apellis Pharmaceuticals, Inc
Page 16 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
• Change in macular sensitivity as assessed by mesopic microperimetry for the evaluation of the macular 
functional response.  
Exploratory Endpoints   
• Change from baseline in NEI VFQ -25 composite score at Month 12 and  Month 24.  
• Change from baseline in NEI VFQ- 25 near activity subscale score at Month 12 and Month  24 (in 
select countries) . 
• Comparison between study eye and fellow eye in change in GA lesion size from baseline to Month 12 and Month 24 .  
• Binocular maximum reading speed as assessed by MNREAD  or Radner Reading Charts over time (in 
select countries).  
• Binocular critical print size as assessed by MNREAD or Radner Reading Charts over time (in select 
countries) . 
• Relationship between genetic polymorphisms associated with AMD with GA progression and r esponse 
to pegcetacoplan . 
• Incidence of new onset of subclinical CNV in the study eye .  
• Assess sensitivity and specificity of a digital reading speed application to detect disease progression / regression  (optional, select sites) . 
• Assess sensitivity and spe cificity of a digital visual function application to detect disease progression / 
regression  (optional, select sites) . 
Safety Endpoints  
• Incidence and severity of ocular  and systemic treatment -emergent adverse events .  
• Incidence of anti -therapeutic antibodi es directed against pegcetacoplan . 
• Incidence of new active CNV in the study eye.  
Analysis of Primary Efficacy Endpoint  
The primary efficacy endpoint is the change from baseline to Month 12 in the total area of GA lesion(s) in eyes injected with pegcetacoplan , either monthly (PM) or every -other month ( PEOM ), or sham injections . GA lesion area 
(mm
2) as measured by a quantified central reading center based on FAF images . The primary analysis will be the 
comparison of pegcetacoplan , either monthly (PM) or every -other month ( PEOM ) versus the combined 2 sham arms 
(the 2 sham arms will be combined into a single ‘control’ group).  
The null and alternative hypotheses for the primar y efficacy analysis are:  
H0: µS = µ PM   vs  H A:  µ S ≠ µ PM , and  
H0: µS = µ PEOM  vs  H A:  µS ≠ µ PEOM  
Note: here µ indicates each group’s respective mean change from baseline to Month 12 in GA lesion area for the comparison of the primary endpoint.  
A mixed effect model for longitudinal data will be used to analyze the change from baseline in GA lesion area. The 
model will include treatment, and presence of CNV in the fellow eye as fixed effects; baseline GA lesion area (at 
screening), time (in months) as a factor; as well as the time  × treatment interaction term . All available data up to 12 
 
 
Apellis Pharmaceuticals, Inc
Page 17 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
months will be included in the model for the primary analysis . The mean cha nge  from baseline to 12 months will be 
estimated from the model ( ie, least square [LS] mean) and compared between each of the pegcetacoplan  arms to the 
sham control . For other time poi nt of interes t, LS mean change from baseline will be estimated and compared 
between treatments . Unstructured variance covariance will be used,  
For the analysis of final study data, a similar model including data up to 24 months will be used and LS means at  
time points  of interest will be estimated and compared between treatment.  
This study is expected to have an approximately 5 DMC  data reviews . Allocating an alpha level of 0.0001 for each 
DMC  data review, the alpha level remains for the efficacy analysis at 0.0495 to maintain an overall study alpha of 
0.05.  
The hypothesis testing strategy for the primary and secondary efficacy endpoints will be based on the Gate -keeping 
multiple testing proced ures controlling for the study wide type I error strongly at 2- sided 0.0495 as follow s:  
Step 1. The mean GA lesion growth at 12 months will be compared between the PM group and the Control at 
the α level of 0.0495. If the null hypotheses of no difference between groups in this step is rejected, the testing 
proceeds to Step 2  and Step 3 . If it’s not rejected, the testing procedure stops at this step.  
Step 2. The mean GA lesion growth at 12 months will be compared between the PEOM group and the Control at the α1 level. If the null hypotheses of no difference between groups in this step is rejected, the  α1 level will 
be passed down to Step 3 . The actual value of α1  will be specified in the SAP and it will be defined to ensure 
an adequate power of at least 80%  for the comparison in this step.  
Step 3. The mean GA lesion growth at 24 months will be compared between the PM group and the Control at 
the α level of 0.0495 if the null hypotheses are rejected at both Step 1  and Step 2 ; or at the α level of (0.0495 – 
α1) if Step 2  testing does not reject the null hypothesis. If the null hypothesis at this step is r ejected, the α level 
used at this step will be passed down to the next step of testing. If it’s not rejected, the testing procedure stops at this step.  
Step 4 . The prioritization and alpha allocation for the remaining secondary endpoints will be specified in the 
SAP.  
The following sensitivity and supportive analyses will be performed to evaluate the robustness of the results from 
the primary analysis method:  
• Analyses will be repeated using the mITT and per-protocol sets  
• Primary and secondary endpoints will  also be summarized with no pooling of the  2 sham arms . The 
comparison for pegcetacoplan  and sham injection within each dose regimen ( ie, PM vs SM and PEOM  
vs SEOM) will be conducted  
• Multiple imputation (MI) methods and other sensitivity analyses will be e xplored,  and details will be 
provided in the SAP  
Analysis  for Key Secondary and Secondary Endpoint(s)  
The key secondary and secondary endpoints will be analyzed in the same fashion as the primary endpoint using 
mixed effect model . The binary secondary endpoints will be analyzed using Cochran -Mantel -Haenszel test stratified 
by the randomization stratification factors . Hypothesis testing for  3 key secondary endpoints will be performed in 
the order specified . The SAP will provide more details on multiplicity a djustment and the approach for alpha 
spending among the endpoints .  
Sample Size Justification 
 
 
Apellis Pharmaceuticals, Inc
Page 18 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Subjects will be randomized in a 2:2:1:1 ratio to receive tre a tment with pegcetacoplan  monthly, pegcetacoplan  every  
other  month, sham monthly, or sham every other  month . The annual growth rate in GA lesion area is expected to 
have a mean of 1.47, 1.70 and 2.13 mm2/year for pegcetacoplan  monthly, pegcetacoplan  every -other -month , and 
sham -pooled groups , respectively, as estimated from the results of a Phase  2 trial f or pegcetacoplan. The standard 
deviation of the lesion growth is estimated to be 1.50 mm2 based on the same Phase  2 trial data or 1.2 5 mm2 based 
on natural history data.27 ie, With a sample size of 20 0 subject s in each group (ie, a total enrollment of 600 subject s) 
and the observed annual growth rate in GA lesion area  from Phase  2 trial for pegcetacoplan, the study will have 
99.2% power to show the difference between PM and sham  group and 81.5% power to show the difference between 
PEOM and sham  group using the common standard deviation of 1. 5 mm2 and 2-sided alpha of 0.05. The 
approximation is calculated using PROC POWER one -way analysis of variance , SAS 9.4 . The study power is likely 
larger when utilizing the lon gitudinal data to model the primary endpoint . The actual study power may also vary 
based on the distribution of the strat ification factors ( ie, lesion area at screening, presence of CNV in fellow eye), 
and site enrollment . 
 
 
Apellis Pharmaceuticals, Inc
Page 19 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
3. ABBREVIATIONS  
Abbreviation  Term  
AE adverse event  
AMD age-related macular degeneration  
ATA anti-therapeutic antibodies  
BCVA  best corrected visual acuity  
CH50  classical pathway of complement functional test  
CNV  choroidal neovascularization 
CRF (eCRF)  case report form (electronic CRF ) (used interchangeably) 
DA disk area  
DCFP  digital color fundus photography 
DMC data monitoring committee  
EDC  electronic data capture 
EOM  every other month 
ERG  electroretinography 
ERM  epiretinal membrane  
ETDRS Early Treatment Diabetic Retinopathy S tudy 
FAF fundus autofluorescence 
FFA/FA  fundus fluorescein angiography or fluorescein angiography 
FRI functional reading independence index  
FSH follicle -stimulating hormone  
GA geographic atrophy 
GCP  Good Clinical Practice  
HCG  human chorionic gonadot ropin 
IB investigator’s brochure 
ICF informed consent form  
 form  
ICH International Council for Harmonis ation  
IEC independent ethics committee  
 
 
Apellis Pharmaceuticals, Inc
Page 20 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Abbreviation  Term  
IOP intraocular pressure 
IRB institutional review board  
ITT intent- to-treat 
IV intravenous 
IVT intravitr eal 
IWR  interactive web response 
LH luteinizing hormone 
LL-BCVA  low luminance best corrected visual acuity  
LLD  low luminance deficit 
MedDRA  Medical Dictionary for Regulatory Activities 
mITT  modified intention to treat  
MNREAD Minnesota Low -Vision Reading Test 
MOP  manual of procedures 
NEI VFQ -25 National Eye Institute Visual Functioning Questionnaire 25- Item Version  
NIR near infrared reflectance  
NOEL  no observable effect level 
NL-BCVA  normal luminance best  corrected visual acuity 
OCT  optical cohe rence tomography 
OCT -A optical coherence tomography angiography 
PEG  polyethylene glycol 
PEG40  polyethylene glycol (40- kDa nominal molecular weight)  
PEOM  pegcetacoplan  every -other- month  
PI principal investigator  
PK pharmacokinetics 
PM pegcetacoplan  monthly 
PP per protocol 
RPE retinal pigment epithelium  
SAE  serious adverse event  
SC subcutaneous 
 
 
Apellis Pharmaceuticals, Inc
Page 21 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Abbreviation  Term  
SC5b -9 soluble terminal complement complex  
SD-OCT  spectral domain optical coherence tomography 
SEOM  sham e very-other -month 
SM sham monthly  
SOP standard  operating procedures  
TEAE treatment -emergent adverse event  
t1/2 terminal elimination half -life 
VA visual acuity 
VEGF  vascular endothelial growth factor 
WOCBP  women of child bearing potential 
WONCBP  women of nonchildbearing  potential 
  
 
 
Apellis Pharmaceuticals, Inc
Page 22 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
4. INTRODUCTION 
4.1. Background  
This study is being conducted as part of a series of studies for the clinical development of 
pegcetacoplan  for advanced Age- related Macular Degeneration (AMD) (neovascular AMD and 
geographic atrophy [GA]). The trial will be conducted in complian ce with this protocol, Good 
Clinical Practice (GCP), and applicable regulatory requirements . The subject population will 
comprise adult male and female subjects with GA secondary to AMD. 
4.1.1. Age-Related Macular Degeneration  
Age-related  macul ar de generation  is the l eading cause of severe vision loss in people over the age 
of 65 in the United  States  and other We stern  countries.2 In the United States, about 1.75 million 
people have the advanced forms of AMD.3 The early signs of AMD (drusen and pigmentary 
changes) are common in individuals over age 65 and precede the late stage forms, which are 
visually devastating. The late stage forms of AMD are classified into either macular 
neovascularization (neovascular, wet, or exudative AMD) or GA. 
Geographic Atrophy is a disease characterized by thinning and loss of the retinal pigment 
epithelium (RPE) and concurrent atrophy of photoreceptors and choriocapi llaris.4,5,6  Clinically, 
GA is characterized by gradually expanding atrophy leaving islands of dead retinal cells in the 
back of the eye. Although GA can result in significant visual function deficits in reading, night 
vision, and dark adaptation, and produce dense, irreversible scotomas in the visual field, the initial decline in visual acuity  may be relatively limited if the fovea is spare d. When the fovea is 
involved, GA quickly causes blindness.  
Genetic susceptibility has become increasingly recognized as a risk factor and important 
contributor to AMD. More than 19 genetic polymorphisms have been demonstrated to influence 
AMD risk, with as many as 5 of these encoded by genes that modulate the complement system. 
Inflammatory processes, especially those mediated by complement are thought to play a key role in AMD.
5 It is thought that these may contribute to loss of choriocapillaris, photoreceptors , and 
RPE cells .  
GA is responsible for approximately 20% of all cases of legal blindness in North America ( ie, 
BCVA 20/200 or worse) with increasing incidence and prevalence owing to a higher life 
expectancy.4  While there is treatment for exudative AMD with anti-VEGF therapies, no 
approved therapy exists for GA which is usually bilateral and relentlessly progressive. It 
represents a significant unmet need as it leads to si gnificant visual impairment and affects more 
than 5 million people worldwide.13 
An overview of available information regarding pegcetacoplan  follows below. Further details 
can be found in the pegcetacoplan  inves tigator’s brochure (IB) .26 
4.1.2. Pegcetacoplan 
Pegcetacoplan is a PEGylated cyclic peptide inhibitor of complement C3 . Pegcetacoplan  is 
formed by 2 identical pentadecapeptides  (combining a bioactive cyclic tridecapeptide C3 -
 
 
Apellis Pharmaceuticals, Inc
Page 23 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
inhibiting moiety and a 2-amino acid linker) covalently coupled to each end of a linear 40 kDa 
polyethylene glycol (PEG) chain. T here are 2 peptide moieties per molecule of pegcetacoplan . 
The peptide portion of the drug binds to complement C3 and is a broad inhibitor of the complement cascade, a biological process that is part of innate immunity and is involved in 
multiple inflammatory processes . The PEGylation of the molecule imparts slower cl earance from 
the vitreous humor following administration.  
Pegcetacoplan Intravitreal Injection 1 5 mg /0.1 mL will be provided as a 150 mg/ mL sterile 
solution of pegcetacoplan  in stoppered glass vials. Pegcetacoplan is a sterile, isotonic solution in 
acetate -buffer, pH 5.0, containing trehalose. The drug product is packaged in 2R clear Type I 
glass vials with 1 3 mm FluroTec-coated chlorobutyl grey stoppers and sealed with 13 mm 
aluminum/polypropylene flip-off type seals.  
4.1.3. Nonclinical Data  
This section is intended to briefly summarize information on the safety, tolerability,  and PK of 
intravitreal ( IVT), intravenous (IV)  and subcutaneous ( SC) injections of pegcetacoplan . For 
complete and detailed information, refer to the IB. 
As pegcetacoplan  is only pharmacologically active in primates, the pivotal IVT toxicologic al 
studies have been conducted in cynomolgus monkeys. The safety and tolerability of 
IVT-administered pegcetacoplan has been assessed in a Good Laboratory Practice 
(GLP )-compliant pivotal chronic (9- month) repeat -dose study in cynomolgus monkeys. In 
addition, 2 GLP -compliant 2 -month ocular bridging studies (the first comparing drug substance 
from  2 different CMOs,  the second assessing the safety and tolerability profiles of 3 different 
formulations to support the Phase 3 clinical study) have been conducted in cynomolgus monkeys 
as well . . Pegcetacoplan  was observed to be minimally immunogenic in the 9-month study a s 
evidenced by a lack of circulating antibodies in the majority of monkeys studied. The NOEL for chronic (9-month) IVT dosing was concluded to be >24.8 mg /eye. The results of this 9 -month 
chronic study in cynomolgus monkeys support the safety of chronic IVT injections of pegcetacoplan  at monthly or bimonthly intervals in humans. 
PK assessments included in the chronic (9-month) study revealed serum concentrations of pegcetacoplan  that were approximately dose-proportional 24 hours after the first IVT dose. The 
serum t
1/2 of IVT -administered pegcetacoplan, determined in a separate PK assessing a 
10 mg /eye dose (in 50 µL), was 10.4 days although the pegc etacoplan  levels measured in the 
serum following infrequent IVT administration are  orders of magnitude lower than 
pharmacological serum levels achieved with SC or IV administration. 
Additional nonclinical  studies in monkeys and rabbits, including assessments of other routes of 
administration (SC and IV), have further defined pegcetacoplan ’s safety profile . . Pegcetacoplan  
has been shown to be generally tolerated through all 3 routes of administration assessed (IVT, 
SC, and IV), with no adverse effects observed in safety pharmacology studies ( in vivo  
cardiopulmonary telemetry and in  vitro  hERG inhibition assay) and genotoxicity studies (Ames, 
in vitro aneugenicity and clastogenicity in TK6 cells, and in vivo  clastogenicity in mouse 
micronuclei) .  
 
 
Apellis Pharmaceuticals, Inc
Page 24 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
 
Apellis Pharmaceuticals, Inc
Page 25 of 164
Confidential
CCI
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
 
Apellis Pharmaceuticals, Inc
Page 26 of 164
Confidential
CCI
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
4.1.4. Clinical Data  
The initial safety and tolerability of pegcetacoplan  following IVT administration in humans was 
tested in an open- label, single dose escalation, Phase I clinical study in patients with wet age-
related macular degeneration under protocol POT-CP043014 ([STUDY_ID_REMOVED]). The study was 
conducte d in multiple ophthalmology clinical sites in the US and Australia . A single dose of 
pegcetacoplan  was administered on Day  1 to patients suffering from wet AMD currently 
receiving anti -VEGF standard of care. Three escalating doses of pegcetacoplan  administered IVT 
were studied . Three subjects received 4  mg; 3  subjects received 10  mg, and 7 s ubjects received 
20 mg . No serious adverse events (SAEs) or drug- related adverse events (AEs) of concern were 
observed. It was concluded that administration of a single dose of pegcetacoplan  IVT up to 
20 mg is safe and well  tolerated .  
A Phase 2 study (Protocol POT -CP121614; NCT 02503332) to assess the safety, tolerability,  and 
evidence of activity of multiple intravitreal injections  of pegcetacoplan  in subjects with 
geogr aphic atrophy secondary to AMD has been completed . The study was conducted at multiple 
ophthalmology clinical sites in the US, Australia,  and New Zealand . Subjects were randomized 
in a 2:1:2:1 manner to either receive pegcetacoplan  IVT 1 5 mg  monthly for 12 months; s ham 
IVT monthly for 12 months; pegcetacoplan  IVT 1 5 mg  every other month for 12 months; or 
sham IVT every other month for 12 months.  
This study demonstrated a statistically significant slowing of disease progression at Month 12 at 
the pre specified  alpha of 0.1. P egcetacoplan  administered monthly showed a 29% ( P=.008) 
reduction in the rate of GA lesion growth compared to sham and pegcetacoplan  administered 
every other month showed a 20% ( P=.067) reduction. P egcetacoplan  has been generally well 
tolerated . The most frequently reported AEs  have been related to the injection procedure 
(intravitreal injection), which are common ly found in this type of study. An imbalance in new 
active choroidal neovasculari zation ( CNV) in subjects treated with pegcetacoplan  was observed 
and the risk of developing new exudation may be increased in subjects with a prior history of 
neovascular AMD in the fellow eye. One subject in the sham arm, 1/81 (1%) was observed to 
have developed new active study eye exudation compared with 2 5/165 (15 %) subjects that 
received pegcetacoplan  IVT injections, 26 subjects in total. Of the 25 pegcetacoplan  treated 
subjects with new active CNV , 18 subjects received PM treatment and 7 subjects received 
PEOM treatment.  
Seventeen of the 25 (68%)  subjects that developed new active study eye CNV had a prior history 
of neovascular AMD in the nonstudy fellow eye. No significant imbalance in history of neovascular AMD in the fellow eye was observed among the 3 arms to explain the imbalance in new exudation observed in study eyes. Visual acuity data did not demonstrate clear differences between subjects developing new study eye exudation compared with those that did not. 
A Phase 1b study (Protocol APL2-103; NCT 03777332) to assess the safety of pegcetacoplan  in 
subjects with GA secondary to AMD and low vision is currently ongoing. This study is being 
conducted at multiple ophthalmology clinical sites across the US. Subjects receive monthly 
treatment with intravitreal pegcetacoplan  for 24 months. 
 
 
Apellis Pharmaceuticals, Inc
Page 27 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
4.1.5. Rationale 
4.1.5.1. Rationale for Pegcetacoplan for  Treatment of Geographic Atrophy  
The rationale for the use of a complement inhibitor in patients with AMD is based on evidence 
from both human and animal studies. Human biochemical, genetic, and clinical lines of evidence 
indicate that the complement system plays a role in the etiology of AMD . Complement 
components including C3, the membrane attack complex , and complement factor H , are present 
in drusen and basal laminar deposits in eyes from patients with AMD.7,8,9,10  Genetic variants of 
complement factor H ,8,11,12,13,14 C3,15,16 complement factor I17 and other complement 
components18,19,20 have been associated with altered risks for the development of both the 
neovascular and atrophic forms of AMD. Patients with AMD also have signs of systemic complement activation, exhibiting higher serum levels of Complemen t Fact or B, C3a, C5a, 
SC5b-9 (soluble terminal complement complex) , C3d, and Ba compared to age- matched 
controls.
21,22,23,24  
4.1.6. Dose Selection  
A single dose of 15 mg /0.1 mL  injection administered monthly or EOM for 24  months will be 
tested in this study (see Section  7.3.1). Pegcetacoplan  was well  tolerated in a panel of animal 
toxicology studies. A 9 -month, repeat-dose GLP study in cynomolgus monkeys was conducted 
to evaluate the safety of IVT injections of pe gcetacoplan  at doses up to 24.8 mg /eye at a 
frequency of 1 injectio n every 4 weeks.  
In this pivotal chronic toxicological study conducted in monkeys, the NOEL was established as >24.8 mg  of pegcetacoplan  delivered intravitreally every 4 week s for 9 months using a 100 µL 
injection . The volume of the human vitreous is approximately 4  mL, which is approximately  
2.7-fold larger than the mean vitreous volume of cynomolgus monkeys, 1.5 mL.
25 Based on the 
difference in vitreous volume between man and cynomolgus and the NOEL defined in nonhuman primates, the human equivalent dose was determined to be 67 mg /eye every 4 week s. 
The dose (15 mg/injection) of pegcetacoplan  that will be evaluated in this clinical study is 
expected to result in drug concentrations approximately 4.5-fold lower that the NOEL observed in cynomolgus monkeys.  
To support appropriate assessments of dose response to pegcetacoplan , pegcetacoplan  is 
administered in  2 different frequencies in the study: monthly and every other month.  
Physician feedback injecting a 200 mg/mL solu tion in the Phase 1 (Study POT-CP043014; 
[STUDY_ID_REMOVED]) trial confirmed that 150 mg/mL is the highest practical concentration that can be 
routinely administered, which set the dose of the Phase 2 trial to 1 5 mg  (ie, 0.1 mL of a 
150 mg/mL solution) . The 15 -mg dose given monthly was found to be the most efficacious in the 
Phase 2 trial. The 1 5 mg  dose given every other month demonstrated slightly less efficacy but 
offers a reduced  treatment burden for patients and physicians.  
4.2. Risk/Benefit  
The Phase 1 (Study POT -CP043014; [STUDY_ID_REMOVED]) and Phase 2 (Study POT-CP121614; 
NCT 02503332) studies provide supporting evidence of a positive benefit-risk profile for the use 
of pegcetacoplan  in treating patients with AMD, specifically patients with GA . These 
 
 
Apellis Pharmaceuticals, Inc
Page 28 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
prelimin ary res ults of an up to 28% reduction of GA progression rate support the evaluation of 
pegcetacoplan in a Phase 3 study.  
The reported safety data from these studies demonstrated an acceptable safety and tolerability 
profile with no clinically significant safety concerns observed . A total of 178 patients have 
received at least  1 dose (15 mg/injection) of pegcetacoplan  as part of these studies. In the Phase 2 
study in patients with GA an imbalance in new exudation in subjects treated with pegcetacoplan  
was observed . Section  4.1.4 provides a summary of the study design and key results from both 
studies. 
The safety monitoring practices employed by this protocol (complete ophthalmologic exam, IOP 
monitoring, OCT, fluores cein angiography, vital signs, hematology, serum chemistry, urinalysis, 
physical exam, vital signs, and AE questioning) are adequate to protect the subjects’ safety. There are also risks associated with the ophthalmic p rocedures required for participants in this 
study. However, these are all standard procedures that are widely performed in ophthalmology. 
In the days following any IVT injection, patients are at risk of developing sterile or infectious 
intraocular inflamma tion ( eg, endophthalmitis). In recent  studies conducted with pegcetacoplan  
IVT from a single manufacturer, events of transient moderate and severe intraocular 
inflammation have been observed. Other risks of IVT injection include traumatic cataract, retinal 
detachment, increased IOP,  and hemor rhage.  
The amount of blood (See Section  9.16) planned for collection from each subject over the 
24 months of the study does not pose an undue risk in this patient population. 
There is a potential health benefit for tri al participants from receipt of study drug. If efficacious, 
pegcetacoplan  is expected to alter the course of GA and slow its rate of progression . 
 
 
 
Apellis Pharmaceuticals, Inc
Page 29 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
5. STUDY OBJECTIVES  
5.1.1. Primary Objective  
To evaluate the efficacy of pegcetacoplan  compared to sham injection in patient s with GA 
secondary to AMD assessed by change in the total area of GA lesions from baseline as measured 
by fundus autofluorescence ( FAF). 
5.1.2. Key Secondary Objectives  
To evaluate the efficacy of pegcetacoplan  compared to sham injection in patients with G A 
secondary to AMD with  respect to: 
• Monocular maximum reading speed (study eye), as assessed by Minnesota Low-
Vision Reading  Test  (MNREAD) or Radner Reading Charts (in select countries)  
• Functional Reading Independence (FRI) index score 
• Normal luminance bes t corrected visual acuity score (NL -BCVA) in the study eye  
5.1.3. Secondary Objectives  
• To evaluate the efficacy of pegcetacoplan  compared to sham injection in patients with 
GA secondary to AMD with  respect to: 
o Low luminance best corrected visual acuity score (L L-BCVA) in the study 
eye  
o Low luminance deficit (LLD) in the study eye 
o Total area of GA lesion(s) in the study eye 
o Monocular critical print size (study eye), as assessed by MNREAD or Radner Reading Charts (in select countries)   
o National Eye Institute Visua l Functioning Questionnaire 25- Item Version 
(NEI VFQ -25) distance activity subscale score (in select countries)  
o Macular functional response as assessed by mesopic microperimetry  
5.1.4. Safety Objectives  
• To evaluate the safety and tolerability of pegcetacoplan  compared to sham  injection 
in patients with GA secondary to AMD as indicated by: 
o Incidence and severity of ocular and systemic treatment -emergent adverse 
events  
o Incidence of anti -therapeutic antibodies directed against pegcetacoplan  
o Incidence of new active C NV in the study eye 
 
 
Apellis Pharmaceuticals, Inc
Page 30 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
5.1.5. Exploratory Objectives 
• To evaluate the efficacy of pegcetacoplan  compared to sham injection in patients with 
GA secondary to AMD as indicated by: 
o NEI VFQ-25 composite score  
o NEI VFQ-25 near activity subscale score (in select countries)  
o Comparison between study eye and fellow eye in change in GA lesion size  
o To evaluate the binocular maximum reading speed as assessed by MNREAD 
or Radner Reading Charts (in select countries)  
o To evaluate the binocular critical print size as assessed by MNREAD or Radner Reading Charts (in select countries)  
• To evaluate the relationship between genetic polymorphisms associated with AMD 
with GA progression and response to pegcetacoplan  
• To evaluate the incidence of new onset of subclinical CNV in the study eye 
• To assess sensitivity and specificity of a digital reading speed application to detect disease progression / regression (optional, select sites)  
• To assess sensitivity and specificity of a digital visual function application to detect 
disease progression / regression (optional, select sites)  
 
 
Apellis Pharmaceuticals, Inc
Page 31 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
6. PATIENT POPULATION  
The study population includes approximately 600 subject s to be randomized at approximately 
100 multinational sites . To participate in the study, subjects must be diagnosed with GA of the 
macula secondary to AMD in the study eye.  
6.1.1. Inclusion Criteria  
The study eye must meet all inclusion criteria . If both eyes meet the inclusion criteria, the eye 
with the worst normal luminance visual acuity at the screening visit will be designated as the 
study eye. If both eyes have the same visual acuity, the right eye will be selected as the study eye.  
Ocular -specific inclusion criteria apply to the study eye  only, unless otherwise specified. 
1. Age ≥ 60 year s. 
2. Normal Luminance best corrected visual acuity of 24 letters or better using Early 
Treatment Diabetic Retinopathy Study (ETDRS) charts ( approximately 20/320 S nellen 
equivalent). 
3. Clinical diagnosis of GA of the macula secondary to AMD as determined by the 
investigator and confirmed by the reading c enter.  
4. The GA lesion m ust meet the following criteria as determined by the central reading 
center’s assessment of FAF imaging at screening:  
a. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas [DA] respectively) . 
b. If GA is multifocal, at least 1 focal lesion must be ≥1.25  mm2 (0.5 DA), with the overall aggregate 
area of GA as specified above in 4a. 
c. The entire GA lesion must be completel y visualized on the macula centered image and must be able to 
be imaged in its entirety and not contiguous with any areas of peripapillary atrophy.  
d. Presence of any pattern of hyperautofluorescence in the junctional z one of GA . Absence of 
hyperautofluoresce nce ( ie, pattern  = none) is exclusionary.1 
5. Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images as determined by the investigator.  
6. Meets th e following criteria related to microperimetry:  
a. Able to detect fixation target.  
b. Total elapsed time to complete the 10 -2 68-point  exam is ≤3 0 minutes in duration .  
c. Fixation losses  must be ≤20% .  
d. Subject is willing and able to undertake microperimetry assessment in the opinion of the investigator.  
7. Female subjects must be: 
a. Women of non–c hildbearing  potential (WONCBP), or  
b. Women of child bearing  potential (WOCBP) with a negative  serum  pregnancy test at screening and 
must agree to use protocol defined methods of contraception for the duration of the study and refrain 
from breastfeeding for th e duration of the study.  
 
 
Apellis Pharmaceuticals, Inc
Page 32 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
8. Males with female partners of child bearing potential must agree to use protocol defined 
methods of contraception and agree to refrain from donating sperm for the duration of the 
study. 
9. Willing and able to give informed consent and to comply with the study procedures and assessments.  
6.1.2. Exclusion Criteria  
Ocular specific exclusion criteria apply to the study eye  only, unless otherwise specified . 
1. GA second ary to a condition other than AMD such as Stargardt disease, cone rod 
dystrophy, or toxic maculopathies like plaquenil maculopathy in either eye. 
2. Spherical equivalent of the refractive error demonstrating > 6 diopters of myopia or an axial length >2 6 mm. 
3. Any history or active CNV, associated with AMD or any other cause, including any evidence of retinal pigment epithelium rips or evidence of neovascularization anywhere based on SD-OCT imaging and/or fluorescein angiography as assessed by the reading center . 
4. Presence of an active ocular disease that in the opinion of the investigator compromises or confounds visual function, including but not limited to, uveitis, other macular diseases 
(eg, clinically significant epiretinal membrane [ ERM ], full thickness macular hole) or 
uncontrolled glaucoma/ocular hypertension). Benign conditions in the opinion of the 
investigator such as peripheral retina dystrophy are not exclusionary. 
5. Intraocular surgery (including lens replacement surgery) within 3 months prior to random ization .  
6. History of laser therapy in the macular region. 
7. Aphakia or absence of the posterior capsule. Note: YAG laser posterior capsulotomy for posterior capsule opacification done at least 60 days prior to screening is not exclusionary. 
8. Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention during the study period or, in the opinion of the investigator, could compromise visual function during the study period.  
9. Any contraindication to IVT injection including current ocular or periocular infection.  
10. History of prior intravitreal injection .  
11. Unable to perform microperimetry reliably in the opinion of the investigator. 
12. Prior participation in another interventional clinical study for intravitreal therapies in either eye (including subjects receiving sham). 
13. Prior participation in another interventional clinical study for geographic atrophy in either eye including investigational oral medication and placebo. 
14. Participation in any systemic experimental treatment or any  other systemic 
investigational new drug including within 6 week s or 5 half- lives of the active ingredient 
 
 
Apellis Pharmaceuticals, Inc
Page 33 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
(whichever is longer) prior to the start of study treatment. Note: clinical trials solely 
involving observation, over-the-counter vitamins, supplements, or diets are not 
exclusionary.  
15. Medical or psychiatric conditio ns that, in the opinion of the investigator, make consistent 
follow-up over the 24-month treatment period unlikely, or would make the subject an unsafe study candidate. 
16. Any screening laboratory value (hematology, serum chemistry or urinalysis) that in the opinion of the i nvestigator is clinically significant and not suitable for study participation . 
17. Known hypersensitivity to fluorescein sodium for injection or hypersensitivity to pegcetacoplan or any of the excipients in pegcetacoplan  solution.  
6.2. Women  of Childbeari ng Potential  
WOCBP a re de fined  as premenopausal women physiologi cally capable of beco ming pregnant. 
6.3. Women of Non childbearing Potential  
WONCBP are defined as women meeting any of the following criteria:  
• Older than 45 years with amenorrhea for > 2 year s or older than 60 year s with 
amenorrhea for > 1 year . Both confirmed by follicle -stimu lating hormone ( FSH) and 
LH levels.  
• Has undergone hysterectomy, 
• Has undergone bilateral oophorectomy, 
• Has undergone bilateral salpingectomy. 
6.4. Approved Methods  of Contraception  
Approved methods of contraception include:  
• Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation: 
o Oral 
o Intravaginal 
o Transdermal  
• Progestogen-only hormonal contraception associated with inhibition of ovulation: 
o Oral 
o Injectable  
o Implantable 
• Intrauterine device  
• Intrauterine hormone- releasing system  
 
 
Apellis Pharmaceuticals, Inc
Page 34 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
• Bilateral tubal occlusion  
• Vasectomized  partner (provided that partner is the sole sexual partner of the WOCBP 
trial participant and that the vasectomized  part ner has received medical assessment 
of the surgical success) 
• Sexual abstinence (defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the study treatments). Sexual abstinence is only 
accepted when it is the pr eferred and usual lifestyle of the subject. 
Subjects must agree to use an approved method of contraception during the study and 90 days after their last dose of study drug. 
6.5. Discontin uation of Subjects  
A subject may withdraw from the study at any time for any reason without prejudice to his/her future medical care by the physician or at the institution. The investigator or sponsor may withdraw the subject at any time ( eg, in the intere st of subject safety) . The investigator is 
encouraged to discuss withdrawa l of a subject from treatment with  the investigational product 
(IP) with the m edical monitor, when possible. 
Subjects who discontinue treatment with the IP can continue participation in the study and 
should be encouraged to return to the clinical site for as many follow-up visits as they can. In the event that a subject terminate s early  from the study, all early termination procedures should be 
performed even if they are outside the allowed study window.  
The reason for termination, date of stopping treatment with IP , all follow -up information and the 
total amount of IP  administered  must be recorded in the case report form (CRF) and source 
documents. 
 
 
Apellis Pharmaceuticals, Inc
Page 35 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
7. TREATMENT  OF SUBJECTS 
7.1. Allocation  to Treatment  
Each subject will be assigned a unique screening number after signing the informed consent. 
Subjects who complete the study screening assessments and meet all the eligibility criteria will 
be scheduled to enter the study and randomized on Day  1. As part of the screening process, the 
reading c enter will evaluat e FAF, OCT, Digital Color Fundus Photograph (D CFP) , Near Infrared 
Reflectance (NIR) , and f luorescein angiography (FA) to provide an objective assessment of 
subject eligibility . Subjects will be randomized 2:2:1:1 to receive treatment with PM, PEOM , 
sham in jection monthly (SM) or sham injection every  other month (SEOM), respectively . 
Table 1 presents the treatment arms along with the approximate number of subjects and 
injections per arm.  
The randomization scheme will be generated and maintained by the sponsor, or designee. Subjec t randomization will be stratified by GA lesion area at screening (< 7. 5 mm
2; ≥ 7.5 mm2) 
and presence of CNV in the fellow eye (yes; no) . Further details on the randomization 
procedures will be described in the s tatistical analysis plan .  
7.2. Masking and Minimization  of Bias 
The intent of masking is to limit the occurrence of conscious and unconscious bias in the conduct 
and interpretation of the clinical study. Bias could arise from the influence that the knowledge of 
a specific treatment assi gnment may have on the recruitment and allocation of subjects, their 
subsequent care, the assessment of endpoints, the handling of withdrawals, and so on. The 
essential aim of masking, therefore, is to prevent identification of the treatments by the subjec t 
and the masked assessors associated with the conduct of the study until all such opportunit ies for 
bias have passed.  
This is a double- masked study. Designated masked s tudy site staff ( eg, assistant( s), visual acuity  
technicians, OCT technicians, photographers, technicians administering questionnaires, s ubjects , 
reading c enter personnel, the assi gned evaluating physician(s), and the sponsor) will be masked 
to treatment assignment. However, the treating physician and any associated support staff 
involved in performing the intravitreal or sham injections will be unmasked to study treatment. These in dividuals are not allowed to discuss treatment and/or patient outcome with masked study 
staff, including the evaluating physician. The principal investigator must be masked to subjects’ treatment assignment. To prevent bias in treatment assignment, eligible subjects will be randomized using a web-based randomization system. Documentation will be put in place to 
avoid unintentional unmasking during the study. All stu dy roles will be clearly documented on 
the site delegation of authority log and once the roles have been designated and executed, these 
roles should not be switched during the conduct of the study. In unforeseen circumstances, a site 
can contact the sponsor to switch a study staff member from the masked role to the unmasked role but not vice versa. 
 
 
Apellis Pharmaceuticals, Inc
Page 36 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
7.2.1. Unmasking   
In the event of a medical emergency where the knowledge of subject treatment by masked 
individuals ( eg, the subject or his/her physician) is required, an individual investigator (or 
designee) will have the ability to unmask the treatment assig nment for a specific subject and 
share that information with the appropriate parties . All documentation indicating unmasking 
must be retained with the subject’s source documentation in a secure manner. A DMC  will be 
set-up to monitor patient safety and review data. The DMC  will be provided unmasked safety 
data but will be masked to efficacy data unless this data is deemed medically necessary . 
Procedures for DMC  unmasking will be documented in a DMC  Charter .  
For regulatory reporting and if required by local regulations, the sponsor will unmask study 
treatment for all serious, unexpected adverse reactions that are conside red to be related to study 
drug. Subjects who have had their treatment assignment unmasked secondary to a serious or unexpected AE or medical emergency will no longer receive study treatment. However, they 
should continue to complete as many of the follow-up visits as possible. 
The study unmasking for the primary analysis at 12 months will be limited to the analysis team 
and personnel only on an  as-needed basis . All other personnel in the “masked” role will remain  
masked until the end of study. A document listing out the roles and responsibili ties of the 
individuals participating in the unmasking analysis will be provided prior to the unmasking.  
7.3. Dosage and Administration  
7.3.1. Dose  Levels and Treatment Arms  
After randomization and during the treatment phase beginning at Day  1, all subjects will receive 
a single dose of 15 mg  pegcetacoplan /0.1 mL  or sham injection intravitreally either monthly or 
every other month depending on treatment designation as presented in Table 1 below.  
Table 1:  Treatment Arms with Approximate Number of Subjects  
Treatment Arms  
Pegcetacoplan  15 mg/0.1 mL monthly for 24 months (n= approximately 200 subject s; 24 pegcetacoplan  
injections)  
Pegcetacoplan 15 mg/0.1 mL EOM for 24 months (n= approximately 200 subject s; 12 pegcetacoplan 
injections)  
Sham monthly for 24 months (n= approximately 100 subject s; 24 sham injections) 
Sham EOM for 24 months (n= approximately 100 subjects ; 12 sham injections)  
7.3.2. Treatment Administration   
Only qualified study staff and those delegated the responsibility of study drug administration on 
the delegation of authority log should perform this procedure. All staff should be appropriately 
trained on all procedures prior to performing the procedures. Sites should follow the Visit Schedule  for order of procedures and assessments .  
Administration of study treatment ( pegcetacoplan  or sham) can be done on a separate day from 
the assessment visit if both days fall within the visit window . If this occurs on the randomization 
 
 
Apellis Pharmaceuticals, Inc
Page 37 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
visit, then the administration of pegcetacoplan  or sham should be done within 3 days of 
randomization and after approval from the m edical monitor. When  study treatment 
administration is on a day other than a study visit, then the only assessment that must be done on 
the day of study treatment administration is the IOP pre injection . 
If a subject falls outside the visit window for a dosing visit, the dose should be skipped and the subject should be scheduled on time for the next dosing visit. 
7.3.3. Drug  Supplies  
7.3.3.1. Identity of Investigational Product  
Pegcetacoplan will be supplied as a liquid solution in stoppered glass vials and should be stored 
according to the label. Specific instructions for preparing pegcetacoplan  for the IVT injection 
procedure will be provided in the manual of procedures . Pegcetacoplan Intravi treal Injection 
15 mg /0.1 mL (15 0 mg/mL) is a sterile, isotonic solution of pegcetacoplan  in acetate -buffer, pH 
5.0, containing trehalose . The drug product is packaged in 2R clear Type I glass vials with 
13 mm FluroTec-coated chlorobutyl grey stoppers and sealed with 13- mm 
aluminum/polypropylene flip-off type seals.  
Sham will be provided as empty stoppered glass vials and should be stored according to the 
label .  
7.3.3.2. Storage  
Vials should be automatically stored as per the instructions until ready for use. Each vial should only be used once. Vials should not be shaken and should be protected from sunlight.  
7.3.3.3. Accountability  
Pegcetacoplan  drug product and sham vials will be provided to a designee at the study site and 
must be stored in a pharmacy or otherwise locked and secured, at the temperature specified on 
the label . The  drug product supply is accessible only to those individuals authorized by the PI. 
The sponsor will supply sufficient quantities of pegcetacoplan  drug product and sham to allow 
completion of this study. The site should only use the investigational medicina l product provided 
by the sponsor for use in the study. 
Designated  unmasked study staff will provide the study treatments to the subjects in accordance 
with their assigned subject numbers and the randomization schedule. During the study, the 
receipt of the drugs supplied at the clinical site and of study treatment dispensation for each 
subject will be documented in drug accountability records. These drug accountability records are to be kept separate from the patient medical records and other source documents.  
All used vials should be retained by the clinical site until drug accountability monitoring is performed and then returned to the sponsor  or designee  or destroyed per sponsor instructions. At 
the conclusion of the study, any unused IP returned to the sponsor  or designee , or destroyed per 
sponsor instructions, and this will be documented in the drug accountability records. 
 
 
Apellis Pharmaceuticals, Inc
Page 38 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
7.3.4. Intravitreal  Pegcetacoplan Administration  
Subjects receiving active treatment will be administered 0.1 mL  IVT injection of pegcetacoplan  
according to their treatment designation using a thin wall needle. Detailed instructions on drug 
preparation, pre injection  procedures, administration of pegcetacoplan , and post injection  
procedures will be provided in the manual of procedures. 
Clinic staff  involved in the injection tray assembly, anesthetic preparation, and study drug 
preparation and administration will follow appropriate aseptic techniques to minimize the risk of 
potential AEs  associated with IVT injections.  
Administration of pegcetacoplan  is only allowed if pre injection  IOP ≤ 21 mm  Hg. If necessary , 
antiglaucomatous medication can be given to lower the IOP. To minimize  transient  IOP 
elevation after IVT injection of pegcetacoplan , decompression of the eye must  be performed 
before all pegc etacoplan  injections . This is done by applying moderate pressure to the globe with 
cotton swabs for 30-60 seconds during anesthetic preparation.  
In addition to the procedures outlined in the protocol and manual of procedures ( MOP ), 
adherence to specific i nstitutional policies associated with IVT injections will be observed.  
7.4. Sham Injection Administration  
The procedure for sham injection will be the same as that used for IVT injection until the actual 
injection but no actual inj ection will occur . The inject ing physician will only touch the study eye 
with the blunt end of the syringe. No needle or medication will be injected inside the eye. Detailed instructions on sham injection procedures and post injection  procedures will be pro vided 
in the manual of procedures .  
Subjects randomized to the monthly or every-other-month sham- injection groups will receive 
sham injection monthly or every other  month, respectively. The same assessments will be 
performed as for the subjects in the pegc etacoplan  groups.  
7.5. Concomitan t Therapies  
Any concomitant medications a participant is receiving at the start of the study, within 30 days 
prior to screening, or that are given for any reason during the study (except for routine 
medications given for ocular procedures required by the protocol, such as topical anesthetic) must be recorded in the source documents and CRF including start and stop date and time, dose, 
route, and indication. In addition, all invasive intraocular procedures from the previous 5 year s 
must also be recorded in the source document s and CRF  including start and stop dates. Surgical 
anesthetics, paramedical or alternative therapies ( eg, acupuncture, herbal supplements) should 
also be recorded in the source documents and CRF within 30 days prior to screening. 
Metoclop ramide or other agents to prevent nausea induced by fluorescein injection may be 
administered at the discretion of the PI.  
7.5.1. Treatment of New Exudation Related to Active Choroidal Neovascularization in 
the Study Eye  and/or Fel low Eye 
The suspected onset or presence of new exudation related to active CNV secondary to AMD in 
the study eye and/or fellow eye must be documented in the source documents and CRF. If the 
 
 
Apellis Pharmaceuticals, Inc
Page 39 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
investigator suspects new exudation related to active CNV in the study eye based on fundus 
examination and/or OCT findings ( eg, subretinal fluid, intraretinal fluid, cystoid macular edema, 
serous pigment epithelial detachment), a fluorescein angiography and Optical Coherence 
Tomography Angiography (OCT- A; select sites on ly) must also be captured following the 
imaging protocol procedure. All images, as outlined above, must be sent to the reading center. The reading center will provide a report indicating whether or not evidence of active, exudative AMD is present or absent , based on the images sent for a ssessment.  
The determination about initiation of anti- VEGF treatment for the exudation related to active 
CNV is the sole responsibility of the investigator. Treatment with anti-VEGF should start after the report is received by the site from the reading center, with the exception of cases with clear 
evidence of disease activity (eg, ; subretinal hemorrhage, extensive subretinal fluid and/or edema, 
and/or presence of subretinal hyperreflective material) that, in the opinion of t he investigator, 
may have a detr imental visual impact if not treated immediately .  
If it is determined that the subject requires anti-VEGF therapy, ranibizumab or aflibercept should 
be selected and administered by the injecting (unmasked) physician. Ranibizumab should be given monthly and aflibercept every other month after 3 monthly loading doses. The frequency 
of aflibercept can be changed to monthly if deemed necessary by the investigator, however the 
physician should refrain from using as- needed treatment (PRN) or treat and extend protocols. 
Every effort should be made to use the same anti-VEGF therapy for a subject during the course of the study and all treatments should be documented in the CRF. 
If anti -VEGF therapy is administered in the study eye on the same day as an pegcetacoplan  (or 
sham) injection, the anti-VEGF therapy shall be administered first and the pegcetacoplan  or 
sham  injection shall occur at least 3 0 min utes after the anti -VEGF injection and only if the IOP 
is ≤21 mm Hg . Anti -glaucomatous medication can be given to lower the IOP to the appropriate 
range to allow for the pegcetacoplan  injection .  
In order to avoid potential unmasking, if anti-VEGF and pegcetacoplan  are given at the same 
visit, the unmasked physician must perform both procedures. If the anti -VEGF therapy is given 
on a separate day from the pegcetacoplan  administration, either the masked or the unmasked 
physician may perform this injection .  
Treatment with anti- VEGF is allowed in the fellow eye . The treatments for the fellow eye can be 
administered accordin g to the site’s standard protocol for CNV treatment. Any treatments or 
therapies administered to the fellow eye within 5 year s of screening and while on study should be 
recorded as a concomitant medication.  
7.5.2. Prohibited Therapies  
The PI should make a determ ination regarding patient continuation of therapies used to treat 
concomitant medical conditions . Therapies as noted in the inclusion/exclusion criteria are 
prohibited as specified. 
7.5.3. Endophthalmitis Treatment  
Endophthalmitis cases  must be reported as SAEs. The decision to treat a participant for 
endophthalmitis or suspected endophthalmitis will be guided by the clinical judgment of the 
investigator and in accordance with local guidelines (as applicable). A culture s ample should be 
 
 
Apellis Pharmaceuticals, Inc
Page 40 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
performed prior to making a decision on treatment. The treatment method (pars plana vitrectomy 
vs intravitreal injection of antibiotics ) and choice of antimicrobial agents are also at the 
discretion of the physician and should follow current standard practice patterns . The decision to 
use IVT steroids ( eg, dexamethasone) for the treatment of endophthalmitis is also at the 
discretion of the physician. 
 
 
Apellis Pharmaceuticals, Inc
Page 41 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
The planned length of participation in the study for each subject is approximately 25 months 
(from the beginning of the screening period through completion of the Month 24 visit). After 
completion of the 24-month treatment period, subjects will be offered entry into a separate open-label study. 
8.1. Study Visit Schedule  
Below is a condensed description of the study visits and the procedures and examinations that will be performed . Please refer to the Visit Schedule  in Appendix A  to Appendix D  for a detailed 
schedule of procedures/assessments for the monthly and EOM visit schedules. Additional safety 
assessments not listed in this section or the flow chart may be performed if considered necessary 
at the discretion of the investigator. 
8.1.1. Screening Period —Within 28 Days P rior to Randomization/ T reatment (Day –28 
to –1) 
8.1.1.1. Visit  1—All S ubjects  
Note: All ophthalmic procedures (including imaging) are to be performed on both eyes, except 
where specified .  
Before any study-specific procedures are performed, the purpose and nature of the study should be explained and the patient should read, sign, and date the Institutional Review 
Board/Independent Ethics Commi ttee (IRB/I EC)-approved Informed Consent Form (ICF) . The 
individual obtaining consent from the patient and a witness, if applicable, should also sign and 
date the ICF . Once the patient has signed the ICF, a screening number should be assigned to the 
patien t. Demograp hic information, significant medical/surgical history within the previous 
5 year s, invasive ocular procedures within the previous 5 year s, and concomitant medications 
used within 30 days prior to screening should be collected (including vitamins and all over -the-
counter as well as prescription medications) . Complete smoking/ tobacco history should also be 
collected.  
Subject eligibility should then be determined by reviewing the inclusion/exclusion criteria and 
the study eye should be selected. Pr ior to the administration of fluorescein, blood and urine 
should be collected for safety labs (including blood for human chorionic 
gonadotropin/follicle -stimulating hormone/luteinizing hormone [ HCG/FSH/LH] , if applicable) 
and vital signs along with a physical examination including weight and height should be performed.  
A complete ophthalmic exam including slitlamp  exam of the cornea, iris, anterior chamber, 
aqueous reaction (cells and flare), dilated fundus exam of the vitreous and retina, and intraocular pressure ( IOP) measurement . Normal luminance BCVA should be performed prior to dilating the 
eyes. Images should be captured as outlined in the Visit Schedule (FAF, NIR, DCFP, FFA) and 
forwarded to the reading center for determination of eligibility if applicable.  
Mesopic microperimetry should be performed on both eyes post dilation of the eyes and 
forwarded to the reading c enter.  
 
 
Apellis Pharmaceuticals, Inc
Page 43 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
8.1.2. Randomization/ Initial Treatment —Day  1—Within 28 Days of S creening  
8.1.2.1. Visit  2—All G roups  
At this visit, all inclusion/exclusion  criteria should  be reviewed prior to randomization and 
dosing, including the determination of eligibility by the reading center . Subjects will be 
randomized using the Interactive Web Response (IWR) System. A complete ophthalmic exam 
including slit lamp  exam of the cornea,  iris, anterior chamber, lens,  and aqueous reaction (cells 
and flare), dilated fundus exam of the vitreous and retina, and IOP measurement will be performed and imaging collected as per the Visit Schedule. 
All assessments should be performed on the same day. All study visits should be scheduled and 
projected based on the Day  1 visit date.  
Blood should be drawn for anti -pegcetacoplan  antibodies.  
Prior to dilating the eyes, all functional tests should be performed (NL- BCVA, LL -BCVA, and 
MNREAD or Radner Read ing Charts [ in select countries ]). Subjects at select sites will be trained 
on how to use the home-based digital applications for visual function and reading speed if the subject decides to participate in this portion . This training mus t occur after completion of all 
functional tests (NL -BCVA, LL -BCVA) . Tests completed using the digital application  at select 
sites (optional) should be completed prior to dilating the eyes but after completion of all 
functional tests and quality of life me asures (NL -BCVA, LL -BCVA, MNREAD or Radner 
Reading Charts [ in select countries] , NEI VFQ-25, and FRI). The subject should be instructed to 
take the electronic device home and to complete the digital application weekly on the same day each week, if possible. The quality of lif e measures (NEI VFQ -25 and FRI) should be 
administered by the masked site staff .  
Imag ing should be performed including FAF, SD- OCT, OCT -A (select sites), endothelial cell 
count (select sites)  and NIR  and sent to the reading c enter for evaluatio n.  
Study drug or sham  injection should be performed by the unmasked physician as described in the 
manual of procedures and the study eye should be monitored post injection as outlined in Section  9.16. A follow-up phone call should be scheduled with the subject 4 ± 2 days after 
randomization Day  1 to assess for any AEs .  
8.1.3. Treatment Phase—24 Months   
8.1.3.1.  Months 1 -12 
8.1.3.1.1. Visits  3-14 (Monthly  and Every -Other Month  Group)  
During this phase, there will be clinic visits every month. Dosing and assessments will occur monthly in the monthly pegcetacoplan  and s ham injection treatment arms . Dosing will occur 
every  other month in the EOM pegcetacoplan  and s ham injection treatment arms, however, the 
subjects will return monthly for assessments (with no dose given).  
A complete ophthalmic exam including slitlamp  exam of the cornea, iris, anterior chamber, lens,  
and aqueous reaction (cells an d flare), dilated fundus exam of the vitreous and retina, and IOP 
measurement will be performed and imaging collected as pe r the Visit Schedule.  
 
 
Apellis Pharmaceuticals, Inc
Page 44 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Blood will be drawn for safety labs, anti -pegcetacoplan  antibodies, and genotyping (Month 2 
only) prior to the administration of fluorescein as per the Visit Schedule . Samples will be 
collected for the clinical repository for those subjects that consent to this portion.  
Prior to dilating the eyes, all functional tests will be performed (NL -BCVA, LL -BCVA, and 
MNREAD or Radner Reading Charts [ in select countries ]). Tests completed using the digital 
application  at select sites (optional) will be completed prior to dilating the eyes but after 
completion of all functional tests and quality of life measures (NL -BCVA, LL -BCVA, 
MNREAD or Radner Reading Charts [ in select countries ], NEI VFQ -25, and FRI). At select 
sites t he subject should be instruct ed to take the electronic device home and to complete the 
digital application weekly on the same day each week, if possible. The subject will be instructed 
to bring back the electronic device for the visits specified in the schedule of events. The quality 
of life measures (NEI VFQ -25 and FRI) will be administered by the masked site staff .  
Mesopic microperimetry should be performed on both eyes (where specified) post dilation of the eyes and forwarded to the reading c enter.  
Imag ing will be performed i ncluding FAF, FFA, SD-OCT, OCT -A (select sites), endothelial cell 
count (select sites)  and NIR  and sent to the reading c enter  for evaluation per the visit schedule.  
Study drug or sham injection should be performed by the unmasked physician as described in the manual of procedures and the study eye should be monitored post injection as outlined in Section  9.16. A follow-up phone call should be scheduled with the subject as outlined in the 
schedule of events.  
In the event that a subject is early terminated from the study, all early termination procedures 
should be performed even if they are outside the allowed study window.  
If the subject would like to discontinue dosing but is amenable to continuing in the study, the site 
shoul d make every effort to have the subject complete as many follow -up visits as possible.  
8.1.3.2. Months  13-24  
8.1.3.2.1. Visits  15-26 (Monthly Group) and 15-20 (Every- Other- Month Group)  
During this phase, clinic visits will follow treatment designation ( ie, the monthly subje cts will 
return monthly for dosing and assessments and the EOM  group will return EOM  for dosing and 
assessments) . At select sites, s ubject s will complete the home -based digital assessments  weekly 
during this period.  
A complete ophthalmic exam including sl itlamp  exam of the cornea, iris, anterior chamber, lens,  
and aqueous reaction (cells and flare), dilated fundus exam of the vitreous and retina, and IOP 
measurement will be performed and imaging collected as per the Visit Schedule.  
Blood should be drawn for safety labs , genotyping, and anti -pegcetacoplan  antibodies prior to 
the administration of fluorescein as per the Visit Schedule . Samples will be collected for the 
clinical repository for those subjects that consented to this portion.  
Prior to dilating the eyes, all functional tests should be performed (NL- BCVA, LL -BCVA, and 
MNREAD or Radner Reading Charts [in s elect countries ]). The quality of life measures (NEI 
VFQ -25 and FRI) should be administered by the masked site staff.  
 
 
Apellis Pharmaceuticals, Inc
Page 45 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Mesopic microperimetry should be performed on both eyes (where specified) post dilation of the 
eyes and forwarded to the reading c enter.  
Imag ing should be performed including FAF, FFA, SD -OCT, OCT -A (select sites), endothelial 
cell count (select sites) and NIR  and sent to the r eadin g center for evaluation  per the visit 
schedule.  
IVT (or sham) injection should be performed by the unmasked physician as described in the 
manual of procedures and the study eye should be monitored post injection as outlined in 
Section  9.16. 
In the event that a subject is early terminated from the study, all early termination  procedures 
should be performed even if they are outside the allowed study window.  
If the subject would like to discontinue dosing but is amenable to continuing in the study, the site 
should make every effort to have the subject complete as many follow-up visits as possible.  
The completion of the 24-month study period occurs approximately 30 days (monthly t reatment 
group) and approximately 60 days (EOM treatment group) after the last visit at which 
investigational product ( IP) is administered . The period following last dose of IP is sufficient to 
evaluate the safety of pegcetacoplan based on its half -life in  the vitreous; further details can be 
found in the pegcetacoplan IB. At the end of the 24-month study period, subjects will have the 
option to enroll in a separate open-label study. 
8.1.4. Early Termination  Visit  
A list of all assessments to be performed at the early termination visit can be found on the Visit 
Schedule. All subjects who end the study early for any reason must complete the e arly 
termination visit, however all efforts should be made to have the subject return for as many 
follow-up visits as possible even if dosing does not occur. All  ophthalm ic procedu res are to be 
performed on BOTH EYES . 
8.1.5. Unscheduled Visit s 
If a subject returns to the clinical site before their next scheduled visit for an assessment of an 
AE or at the request of the physician, all safety assessments should be performed and  any 
additional assessments as deemed medically necessary by the physic ian.   
 
 
Apellis Pharmaceuticals, Inc
Page 46 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
9. ASSESSMENTS  
The following evaluations will be performed during the study as outlined in the Visit Schedule  in  
Appendix A  to Appendix D . Refer to the MOP for detailed descriptions of study- related 
procedures. 
9.1. Informed  Consent  
Written informed consent for participation must be obtained before performing any study-
specific assessments . Informed consent for all subjects should be maintained within the subject 
source docum entation .  
9.2. Demographic Information/ Medical/ Surgical  History  
Demographic information will be collected from all subjects including but not limited to date of birth, race/ ethnicity  (where locally perm itted) . All significant medical conditions and surgeries 
within the past 5 year s should be captured for the subject including chronic and ongoing 
conditions. Any history or current use of tobacco is to be collected. 
9.3. Ocular History/ Ocular Procedures   
Ocular history within the previous 5 year s should be collected and recorded for all subjects. The  
history should include any significant previous ocular surgeries, procedures and/ or medications or treatments used for these conditions.  
9.4. Vital Signs  
Vital signs  consist of body temperature, respiratory rate, blood pressure (systolic and diastolic), 
and heart rate measurements .  
On injection visits, vital signs w ill be measured prior to dosing. Vital signs should be taken with 
the patient in a seated position afte r resting for 5 minutes. Vital signs will be measured before 
venipuncture. 
9.5. Physical Examination  
A physical exam will be performed and should include but should not be limited to an evaluation 
of the eyes, ears, nose, throat, lymph nodes, head, and neurological fu nction . A patient’s height 
and weight should also be measured at screening . If any abnormalities are noted at screening, the 
PI, or designee, should determine the clinical significance of the finding and whether this will 
pose any safety risk to the subject. Any changes from baseline should be noted and the clinical 
significance assessed . Any new, clinically significant, findings should be documented as AEs .  
9.6. Laboratory Analysis of B lood and U rine 
Collection of blood and urine will occur at the study site and the samples will be shipped to a 
central laboratory for analysis . All samples (including urine) should be collected prior to 
treatment and F FA/OCT -A assessments (if applicable) . Procedures for the collection and 
processing of blood and urine are provided in the laboratory manual.  
 
 
Apellis Pharmaceuticals, Inc
Page 47 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Table 2 presents the laboratory and urine analysis that will be performed.  
Table 2:  Laboratory Sampling and Analysis 
Hematology Chemistry  Urinalysis  Other 
Hemoglobin  
Hematocrit  
Red blood cell count   
White blood cell count 
with differential  
Platelet count  Blood urea nitrogen  Creatinine  
Bilirubin (total, direct 
and indirect)  
Albumin  Alkaline phosphatase  Aspartate 
aminotransferase  
Alanine aminotransferase  
Creat ine kinase  
Glucose 
Electrolytes (sodium, 
potassium, chloride, bicarbonate) pH 
Specific gravity  
Protein  
Glucose Ketones Biliru bin 
Blood Nitrite  
Urobilinogen Leukocyte esterase  Genotyping  Anti-pegcetacoplan  Ab  
Human chorionic 
gonadotropin
a  
Follicle -stimulating 
hormoneb  
Luteinizing hormoneb  
 
 
a Serum Pregnancy Test (ie, HCG) will be performed for females of childbearing potential at screening only.  
b FSH and LH will be performed for postmenopausal females at screening only.  
The principal investigator, or designee, must review the results of the screening visit clinical 
laboratory tests (including any retest results) and confirm that these results do not show evidence 
of any medical condition that would make study participation inappropriate. The principal 
investigator, or designee, should also assess any changes from baseline at the follow-up visits and the final visit. Clinically significant laboratory values are to be recorded as AEs . 
9.7. Genotyping  Samples  
The genetic marker sample will be used to evaluate the relationship between genetic polymorphisms associated with AMD with disease progression and response to pegcetacoplan . 
A whole -blood sample will be collected for genetic marker analysis. These samples will be 
collected only for those subjects who consent to this analysis .  
These samples  will be stored as per the clinical repository  guidelines outlined in Section  9.17 if 
the subject consents to this portion of the study. These samples  will be stored up to 15 year s after 
the date of the final closure of the associated clinical database if the patient consented to the 
clinical repository .  
9.8. Urine Pregnancy Test 
Urine pregnancy test will be performed in WOCBP only as outlined in the Visit Schedule in Appendix A  to Appendix D . 
 
 
Apellis Pharmaceuticals, Inc
Page 48 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
9.9. Patient -Reported Outcomes 
Data will be collected via interview -administered questionnaires to assess patient-reported 
outcomes during scheduled visits as outlined in the Visit Schedule. The questi onnaire should be 
administered by the masked site staff and should be performed prior to any other assessments 
being performed that day.  
Questionnaire data will be used to assess subject -reported efficacy of pegcetacoplan  and changes 
in quality of life over time . Questionnaires will be translated into the appropriate language for 
each country or region. 
9.9.1. The National Eye Institute Visual Functioning Questionnaire 25 -Item Version  
(NEI -VFQ)  
The NEI-V FQ is an interviewer-a dmin istered questionnaire designed to a ssess patient-r eported 
visual function (Appendix E). T he NEI-VFQ is to be administered by the masked staff. It is a 25-
item questionnaire with a composite score and covers 12 domains of functional health s tatus and 
well-being (general health, general 
vision, ocular pain, near activities (select countries),  distance 
activities (select countries), social functioning, mental health, role difficulties, dependency, 
driving, color vision, and peripheral vision). Scoring yields 12 subs cales based on the 12 
domains covered in the questionnaire. T hese scales are scored from 0 to 100 with higher scores 
indicating better visual function. The recall period is not specified; however, it is important that 
the patient uses the same recall period each time the questionnaire is administered throughout 
their participation in the study.  
9.9.2. The Functiona
l Reading Independence  (FRI) Index 
The FRI will be interviewer -administered and is an individualized assessment of functional 
reading independ ence ( Appendix F ). The questionnaire has 7 items with  1 t otal index score. 
Higher levels on the scale represent higher functional reading independence. The recall period is 
7 days.  
9.10. Best Corrected  Visual Acuity and Low Lu minance  Best Corrected 
Visual Acuity  
Best corrected visual acuity (including best  corrected visual acuity  under low luminance 
[LL-BCVA ]) will be measured at each visit as per the visit schedule by certified study staff. The 
study staff performing visual acuity should be masked to the treatment  assignment. Best  
corrected visual acuity testing will be assessed on ETDRS chart starting at a d istance of 4  m, 
performed by a certified VA examiner, and should precede any examination requiring administration of eye drops to dilate the eye or any examination requiring contact with the eye.  
The LL- BCVA  acuity will be measured by placing a neutral density trial lens causing a reduction 
of 2.0 log units in luminance. The same requirements apply to measurement of low lum inance 
visual acuity as described above for best corrected visual acuity. Low luminance deficit will be 
auto-calculated .  
A Visual Acui ty Specifications procedure manual and training materials will be provided to all 
sites. All examiners will require certification prior to performing this assessment  as part of the 
study.  
Apellis Pharmaceuticals, Inc
Page 49 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
9.11. Minnesota Low -Vision Reading (MNREAD) Test or Radner Reading 
Charts (in select countries)   
MNREAD Test or Radner Reading Charts ( Appendix G ) should be adminis tered first 
monocularly for both eyes and then binocularly. The Manual of Operations should be referenced 
for a list of versions that sh ould be administered  based on country. These tests should be 
administered prior to dilating the eyes. 
9.12. Home -Based Functional  Digital Applications  (optional,  select sites)  
In addition to in-clinic assessments, visual function and reading speed will al so be evaluated 
using applications on an electronic device. Subjects who decide to participate in this portion will 
be trained on how to use the digital applications during the Day  1 visit and will complete the 
assessments using the digital application in the clinic at Day  1, Months 1-3, Month 6, 12, 18, 
and 24. In-clinic assessments on the digital application should be completed after completion of 
all functional tests and quality of life measures prior to dilating the eyes (NL -BCVA, LL -BCVA, 
MNREAD or Radner Reading Charts [in select countries], NEI VFQ 25, and FRI).  
Subjects will also take home the electronic device to complete visual function and reading speed assessments weekly beginning at Day  1. Subjects should be instructed to complete the 
assessments on the same day each week and at approximately the same time of day each week, if possible. 
9.13. Complete  Ophthalmic Exam  
The comp lete ophthalmic exam will consist of the following: 
• External examination of the eye and adnexa.  
• Routine screening for eyelids/pupil responsiveness (including ptosis, abnormal pupil 
shape,  unequal pupils, abnormal reaction to light , and afferent pupillary d efect).  
• Slitlamp  examination (cornea, anterior chamber, iris, lens, aqueous reaction [ cells and 
flare]). Please see Appendix H  for grading scales.  
• Dilated f undus exam including evaluation of retina and vitreous ( ie, posterior segment 
abnormalities, retinal hemorrhage/detachment, and vitreal hemorrhage density and 
vitreous cells) . Vitreal hemorrhage density and vitreous cells grading scales are 
outlined in Appendix I .  
• IOP measurement —A measurement  of intraocular pressure will be conducted using 
either Tono- Pen or Goldmann applanation tonometer as outlined in the MOP. This 
should be performed prior to dilating the eyes and the same method should be used for all measurements in the same subject throu ghout the study. 
9.14. Ocular  Imaging and Microperimetry   
The following ocular images will be obtained and sent to the reading center as outlined in the visit schedule . A reading c enter manual  along with training materials will be provided to all sites  
which wil l provide information on standardized procedures for the collection, storage,  and 
transmission of all images . Prior to any images being taken at the site, site personnel must be 
 
 
Apellis Pharmaceuticals, Inc
Page 50 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
properly trained and certified and test images and systems and software must be certified and 
validated by the reading c enter . Only trained and certified site staff delegated the responsibility 
of image collection should perform this task. O cular images obtained as part of this study are: 
• Digital Color Fundus Photographs  
• Fluorescei n Angiography  
• Spectral Domain Optical Coherence Tomography imaging  
• Fundus Autofluorescence (Heidelberg Spectralis Instrument)  
• Near  Infrared Reflectance  
• Endothelial Cell Count (Specular Microscopy) : Select sites only  
• Mesopic Microperimetry of the study eye only (at screening, performed on both eyes)  
o To account for the learning curve of this test, the patient is allowed up to 3 
attempts to meet the criteria for this portion  
• Optical Coherence Tomography Angiography (OCT -A): Select sites only   
If a patien t misses a visit during which ocular images should have been taken, the images should 
be collected at the next scheduled study visit. 
In the event that a subject is suspected to have new active CNV in the study eye and/or the 
fellow eye, an SD-OCT  and FFA using the protocol specified procedures should be performed 
and sent to the reading center to confirm the diagnosis ( Section 7.5.1). In addition, in select sites, 
OCT -A should also be captured according to the study imaging protocol and sent to the reading 
center .  
9.15. Postinjection A ssessment  
The study eye will be assessed after the int ravitreal injection of pegcetacoplan  or sham  to ensure 
that the injection procedure and/or the study medication have not endangered the health of the eye. The initial postinjection  assessments should be done within 5 min utes post injection and 
include a gross assessment of vision (light perception, hand motion). If the subject passes the 
gross vision test, he/she can be released from t he clinic . If the subject does not pass the gross 
vision test, IOP must be measured at that time . Additional IOP measurement must be taken 
approximately every 30 minutes thereafter until IOP ≤30 mm Hg  and the subject is able to be 
released from the clinic.  
All subjects receiving an anti -VEGF (ranibizumab or aflibercept) and pegcetacoplan /sham 
injectio n on the same day, should have the IOP measured prior to and after the anti- VEGF 
(prepegcetacoplan ). The second injection  (pegcetacoplan/sham ) can only be given if the  
IOP ≤ 21 mm Hg . Anti glaucomatous medication can be given to lower the IOP. The subject can 
only be released from the clinic if the IOP is ≤30 mm Hg . 
Any subject who develops a significant and sustained raise in IOP (>30 mm  Hg) after any 
injection, should be monitored according to the investigator ’s clinical judgment and may 
undergo additional procedures and measurements of IOP beyond those specified in the protocol 
 
 
Apellis Pharmaceuticals, Inc
Page 51 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
as well as IOP lowering procedures. If any concern or immediat e toxicity is noted, the subject 
will remain at the site and will be treated according to the physician’s clinical judgment.  
9.16. Blood Volume for Study Assessments  
Table 3:  Total Study Blood Volume 
Assay  Number of time 
points  Approxima te 
volume per time 
point * (mL)  Appr oximate 
sample volume 
over course of 
study (mL)—all 
groups  
Anti-pegcetacoplan antibodies  9 2 18 
*Hematology 8 4 32 
**Chemistry (incl. HCG/LH)  8 5 40 
FSH/LH (postmenopausal women 
only) - 5 - 
Genotyping samplea 1 8 8 
Clinical repository (select sites a nd 
only subjects that consent to clinical repository) 5 14 70 
Total blood volume   168 a 
Abbreviations:  HCG=human chorionic gonadotropin; FSH=follicle -stimulating hormone ; LH=luteinizing hormone  
a Represents the standard collection volume planned over the duration of the study, actual volume may vary by 
group and across sites.  
* Volume will vary slightly b etween regions and analyzing labs based on the standard methodology. 
** In some regions, may be included in the chemistry sample based on local methodology . 
 
9.17. Samples for Clinical Repository ( Optional, Select Sites)  
Apellis intends to apply genomic research across the pegcetacoplan  development program to 
explore how genomic variations may affect the clinical parameters associated with and response 
to pegcetacoplan . Select sites will be asked to collect additional whole-blood samples and 
derivatives thereof in a centrally administered facility for the long -term storage of human 
biologic specimens. The collection and analysis of these specimens will facilitate the rational design of new pharmaceutical agents and the development of diagnostic tests, which may allow for individualized drug therapy for subjects in the future. Specimens for the Genetic 
Biorepository will be collected from subjects who give speci fic consent to participate in this 
optional research only and this will only be done at a select group of sites.  
Specimens will be used to achieve the following objectives: 
• To study the association of biomarkers with efficacy, AEs , or disease progression 
• To increase knowledge and understanding of disease biology 
 
 
Apellis Pharmaceuticals, Inc
Page 52 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
• To study drug response, including drug effects and the processes of drug absorption 
and disposition  
• To develop biomarker or diagnostic assays and establish the performance characteristics of these assays  
Future research may suggest other genes, gene categories, proteins, etc. as candidates for 
influencing not only response to pegcetacoplan  but also susceptibility to AMD for which 
pegcetacoplan  may be evaluated . Thus, this additional genomic research may involve the future 
study of additional unnamed genes or gene categories, but only as they relate to AMD disease susceptibility and drug action.  
9.17.1. Approval by the Institutional Review Board or Ethics Committee 
Collection and submission of biological s amples to the c linical repository is contingent upon the 
review and approval of the exploratory research and the c linical repository portion of the N by 
each site’s IRB or IEC and, if applicable, an appropriate regulatory body. If a site has not been 
granted approval for c linical repository sampling, this section of the protocol ( Section  9.17) will 
not be applicable at that site.  
9.17.2. Sample  Collection  
The following samples will be collected for research purposes, including but not limited to research on 
dynamic (non inherited ) biomarkers related to AMD and related diseases, pegcetacoplan , and signaling 
pathways related to AMD and the complement pathway: 
• Residual whole-blood clinical genotyping sample 
• 14-mL whole-blood sample collected  at the specified time  points 
For all samples, dates of consent and specimen collection should be recorded on the associated 
clinical repository page of the eCRF. For sampling procedures, storage conditions, and shipment 
instructions, se e the laboratory manual. 
All collected specimens will be destroyed no later than 1 5 years after the date of final closure of 
the clinical database. The c linical repository storage period will be in accordance with the 
IRB/EC- approved I CF and applicable law s (eg, health autho rity requirements).  
9.17.3. Confidentiality and Data Ownership  
Patient medical information associated with c linical repository specimens is confidential and 
may only be disclosed to third parties as permitted by the I CF (or separate authorization for use 
and disclosure of personal health information) signed by the patient, unless required by law. 
Data derived from c linical repository specimen analysis on individual subjects will generally not 
be provided to the subjects or to study investigators unless required by law . The aggregate results 
of any research conducted using c linical r epository specimens will be available in accordance 
with the effective Apellis policy on study data publication. Any inventions and resulting patents, improvements, and/or know-how originating from the use 
of the c linical repository data will become and remain the exclusive and unburdened property of 
Apellis, including the right to sell, license , or assign the invention to another entity.  
 
 
Apellis Pharmaceuticals, Inc
Page 53 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
9.17.4. Consent to Participate in the Clinical Repository  
The I CF will contain a separate section or separate I CF that will address participation in the 
clinical repository. The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential hazards of participation in the c linical repository. Subjects 
will be told that they are free to refuse to participate and may withdraw their specimens at any 
time and for any reason during the storage period. Subj ects who decline to participate in the 
clinical r epository can still participate in this clinical study . The investigator should document 
whether the patient has given consent to participate by completing the c linical repository 
Research Sample Informed Consent eCRF . In the event of a c linical repository participant’s 
death or loss of competence, the participant’s specimens and data will continue to be used as part 
of the c linical r epository research.  
9.17.5. Withdrawal From the Clinical Repository  
Subjects who give consent to provide c linical repository specimens have the right to withdraw 
their specimens from the clinical repository at any time for any reason. If a patient wishes to 
withdraw consent to the testing of his or her specimens, the inves tigator must inform the sponsor 
in writing of the patient’s wishes using the c linical r epository Patient Withdrawal Form and, if 
the study is ongoing, must enter the date of withdrawal on the Clinical Repository Research Sample Withdrawal of Informed Conse nt eCRF . The patient will be provided with instructions 
on how to withdraw consent after the study is closed. A patient’s withdrawal from this study does not, by itself, constitute withdrawal of specimens from the c linical repository. Likewise, a 
patient’s  withdrawal from the c linical repository does not constitute withdrawal from this portion 
of the study. 
9.17.6. Monitoring and Oversight 
Clinical Repository specimens will be tracked in a manner consistent with GCP by a 
quality -controlled, auditable, and appropriately validated laboratory information management 
system to ensure compliance with data confidentiality as well as adherence to authorized use of specimens as specified in this protocol and in the I CF. Apellis monitors and auditors will have 
direct access t o appropriate parts of records relating to patient participation in the c linical 
repository for the purposes of verifying the data provided to Apellis. The site will permit monitoring, audits, IRB/EC review, and health authority inspections by providing di rect access 
to source data and documents related to the c linical repository samples. 
 
 
Apellis Pharmaceuticals, Inc
Page 54 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
10. SAFET Y EVALUATIONS   
Any clinically significant abnormalities persisting at the end of the study/ early withdrawal or 
end of the post treatment  phase will be followed by the investigator until resolution or until a 
clinically stable endpoint is reached . The study includes a number of evaluations to monitor 
safety including monitoring of AEs , post injection  monitoring, laboratory and urine sampling, 
physical examination, and vital signs.  
10.1. Data Monitoring Committee  
An external, independent data monitoring c ommittee  (DMC) will be formed with the purpose of 
reviewing all data across the conduct of the study on an ongoing basis. The DMC  will follow a 
charter that will outline the frequency of meetings and the roles and responsibilities of all members . The DMC  will meet at the beginning of the study and approximately every 6 months 
thereafter  and will perform a ma sked review of all relevant events on an ongoing basis. An ad 
hoc meeting of the DMC  may be convened by the sponsor or the DMC  chairperson at any time 
between the regularly scheduled DMC  meetings and data reviews, if warranted by new safety 
information or for any other reason. The DMC  will communicate their recommendations to the 
sponsor who will notify the appropriate health authorities according to local regulatory 
requirements .  
 
 
Apellis Pharmaceuticals, Inc
Page 55 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
11. ADVERSE EVENTS  
11.1. Definition  
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether 
or not it is considered drug related. An AE can , therefore be any unfavorable and unintended 
sign, including a clinically significant abnormal laboratory finding, symptom, or disease temporally associated with th e use of an IP, whether or not considered related to the IP. 
Adverse events can be spontaneously reported by the subject and/or in response to an open 
question from the study personnel or revealed by observation and will be recorded during the study at the investigational site. All identified AEs must be recorded and described on the appropriate AE or SAE page of the eCRF. 
Fluctuating or nonsignificant changes in laboratory values do not necessarily qualify for AE 
recording but are still collected and re corded via the appropriate eCRF form , if applicable . If 
these changes in laboratory values are linked to a diagnosis, this diagnosis should be reported as 
an AE, esp ecially if the diagnosis constitutes an SAE or leads to discontinuation of 
administration o f IP. 
11.2. Recording Adverse Events  
Adverse events and SAEs will be collected from the signing of the consent form until the last  
visit or early termination  visit, 30 days after the last IP administration for the monthly treatment 
groups and 60 days after the l ast IP administration for the EOM treatment groups. 
Any events that occur prior to dosing will be categorized as pretreatment events; events occurring after dosing w ill be recorded as treatment- emergent adverse events ( TEAEs ) (start date 
of dosing and, therefore, categorization of the event will be dependent on randomization 
assignment). 
For each AE, the investigator will evaluate and report the onset date (and time i f applicable), 
resolution date (and time if applicable), intensity, causality, action taken, serious outcome, and 
whether or not it caused the subject to discontinue the study. 
If possible, the outcome of any AE that caused permanent discontinuation or was present at the 
end of the
 study should be reported, particularly if the AE was considered by the investigator to 
be related to the IP. Subject
s experiencing AEs that cause interruption or discontinuation of IP , 
or those experiencing AEs that are present a t the last visit or early termination  visit should 
receive follow -up as appropriate. 
All SA Es must be reported to the sponsor/Apellis Safety via eCRF within 24 hours of becoming 
aware of the event, whether or not the event is deemed treatment -related. If the electronic data 
capture (EDC) system is not operational (or for paper-based study[ies]), the site must complete the paper SAE form and email to immediately and  also within 24 hours of 
becoming aware of the event. The reported information submitted as a paper SAE must be entered into the EDC system once it becomes operationa l. 
 
 
Apellis Pharmaceuticals, Inc
Page 56 of 164
Confidential
CCI
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Adverse events will be coded in accordance with the Medical Dictionary for Regulatory 
Activities (MedDRA). If known, the diagnosis of the underlying illness or disorder should be 
recorded, rather than its individual symptoms. 
11.3. Reporting Adverse Events  
The sponsor has the responsibility to inform concerned health authorities, ethic committees, and 
investigators about suspected unexpected serious adverse reactions in line with GCP guidance and applicable regulatory requirements. 
If required, specific SAEs should be reported to the concerned ethic committees in compliance 
with local requirements   
11.3.1. Relationship of Events to Study Treatment  
All AEs that occur during this study will be recorded. The investigator will review each event and assess it s relationship to study treatment (definitely related, possibly related, unlikely related, 
not related, unknown). The date and time of onset, time relationship to drug dosing, duration, and outcome ( recovered/ resolved, recovered/resolved  with sequelae, recovering/resolving, not 
recovered/not resolved, fatal, or unknown) of each event will be noted.  
The following definitions should be considered when evaluating the relationship of AEs and 
SAEs to the study treatment: 
Defin itely 
Related  Event or laboratory test abnormality, with plausible time relationship to drug intake 
Cannot be explained by disease or other drugs 
Response to withdrawal plausible (pharmacologically, pathologically)  
Event definitive pharmacologically or phenomenologically ( ie, an objective and specific 
medical disorder or a recognized pharmacological phenomenon) Re-challenge satisfactory, if necessary  
Possibly 
Related  Event or laboratory test abnormality, with reason able time relationship to drug intake  
Could also be explained by disease or other drugs 
Information on drug withdrawal may be lacking or unclear 
Unlikely  
Related  Event or laboratory test abnormality, with a time to drug intake that makes a relationship 
improbable (but not impossible) 
Disease or other drugs provide plausible explanations  
Not Related  Event or laboratory test abnormality, is plausibly related to the participant’s clinical state, 
underlying disease, or the study procedure/conditions 
Time rela tionship to drug intake makes a relationship unreasonable 
Other obvious causes for event or laboratory test abnormality exist 
Unknown Report suggests an adverse event, however, cannot be judged at this time because 
information is insufficient or contradic tory 
More data for proper assessment is needed, or additional data is under examination 
11.3.2. Severity  of Events  
The following definitions should be considered when evaluating the severity of AEs and SAEs: 
 
 
Apellis Pharmaceuticals, Inc
Page 57 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Mild  Asymptoma
tic or mild symptoms; clinical or diagnos tic observations only; intervention 
not indicated. 
Moderate Minimal, local or non invasive intervention indicated; limiting age -appropriate 
instrumental ADL  a. 
Severe  Medically significant but not immediately life -threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limiting self -care ADLb. 
Note : An experience may be severe but may not be serious, eg, severe headache).  
Abbreviation: ADL=activities of daily living  
A semi colon indicates ‘or’ within the description of the gra de. 
a Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc.  
b Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden.  
11.4. Serious Adverse  Events  
An SAE is any AE or suspected adverse reaction that , in the view of either the investigator or 
sponsor, results in any of the following outcomes: death; life -threatening; inpatient 
hospitalization or prolongation of existing hospital ization ; a persistent or significant incapacity 
or substantial disruption of the ability to conduct normal life functions; or a congenital 
anomaly/birth defect.  
Important medical events that may not result in death, be life- threatening *, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in the above definition.  
Examples of such medical events include allergic bronchospasm requiring intensive treatment in 
an emergency room or at home; blood dyscrasias or convulsions that do not result in inpatient 
hospitalization ; or the development of drug dependency or drug abuse. 
*Life -threatening is defi ned as an AE or suspected adverse reaction, which in the view of either 
the investigator or sponsor places the subject at immediate risk of death as it occurred . It does not 
include an AE or suspected adverse reaction that, had it occurred in a more severe form, might have caused death. 
Unexpected Adverse Event 
An AE is considered “unexpected” if it is not listed in the Reference Safety Information section of the IB. 
11.5. Treatment and Follow-up of A dverse Events  
AEs (whether serious or nonserious), including cl inically significant abnormal laboratory test 
values, will be evaluated by the investigator and treated and/or followed up until the symptoms or value(s) return to baseline or are clinically st able. Treatment of AEs will be performed by 
appropriately trained medical personnel, either at the clinical site or at a nearby hospital emergency room . When appropriate, medical tests and/or examinations will be performed to 
document resolution of the eve nt(s).  
 
 
Apellis Pharmaceuticals, Inc
Page 58 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
AEs continuing after completion of the study will be followed up by telephone or with visits per 
the discretion of the investigator. If possible, the outcome of any AE that caused discontinuation 
from the study or was present at the end of the study should be reported, particularly if the AE was considered by the investigator to be related to the study drug. 
11.6. Pregnancy  
Although pregnancy is not an AE, all pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or disease state) occurring with a female subject or the female p artner of a male subject, must be followed to conclusion to determine their outcome and 
are considered immediately reportable events.  
The pregnancy, suspected pregnancy, or positive pregnancy test must be reported to Apellis Safety within 24 hours of the investigator’s awareness using the paper Pregnancy Report Form. 
The Pregnancy R eport Form shall be signed and dated by the investigator and submitted via 
email to . 
The investigator must follow the subject until completion of the pregnancy and must report the outcome of the pregnancy (eg, delivery, termination, etc.) and neonatal status up to 12 months 
postdelivery. An abnormal outcome is defined as any pregnancy that results in the birth of a child with persistent or significant incapacity  or substantial disruption of the ability to conduct 
normal life functions (fo rmerly referred to as disabilities), congenital anomalies, or birth defects. 
In the event of an abnormal outcome, an SAE Report Form will be required. 
11.7. Disease  Progression  
Normal progression or worsening of the medical condition under study ( eg, vision loss due to the 
progression of GA in either eye ), by itself, does not necessarily constitute an AE  unless the 
change can be reasonably attributed to an action of the test article and  not only to its lack of 
efficacy . Disease progression that requires an intervention ( eg, administration of IVT anti- VEGF 
agents for neovascular AMD ) should be recorded as an AE  in the eCRF .  
11.8. Withdrawal  
Participants may choose to discontinue from treatment or to completely withdraw from this study for any reason at any time without penalty or prohibition from enrolling in other clinical protocols. 
Participants wishing to withdraw from the study completely will be offered an early termination 
visit. This ear ly termination visit will include the examinations outlined in  Section  8.1.5. 
Participants wishing to discontinue treatment but willing to continue with other study procedures, will return to the clinical site for follow -up vis its, as per protocol, until Month 24. 
Additional information on subject discontinuation is provided in Section 6.5. 
 
 
Apellis Pharmaceuticals, Inc
Page 59 of 164
Confidential
CCI
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
12. DATA MANAGEMENT AND STATISTICAL  CONSIDERATIONS  
12.1. Data Collection  
The investigators’ authorized site personnel must enter the information required by the protocol 
on the CRF. A study monitor will visit each site in accordance with the monitoring plan and 
review the CRF data against the source data for completeness and accuracy . Discrepancies 
between source data and data entered on the CRF will be addressed by qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by authorized site 
personnel. Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting .  
12.2. Clinical Data Management  
Data are to be entered into a clinical database as specified in the contract research organization’s  
data management plan . Quality control and data validation procedures are applied to ensure the 
validity and accuracy of the clinical database.  
Data are to  be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to the clinical database, and all corrections are documented in an auditable manner.  
12.3. Statistical Analysis Process  
The study will be analyzed by the sponsor or its agent.  
The statistical analysis plan (SAP) will provide the statistical methods  and definitions for the 
analysis of the efficacy and safety data, as well as describe the approaches to be taken for 
summarizing other study information such as subject disposition, demographics and baseline 
characteristics, IP exposure, and prior and con comitant medications . The SAP will also include a 
description of how missing, unused, and spurious data will be addressed.  
To preserve the integrity of the statistical analys is and study conclusions, the SAP will be 
finalized prior to database lock . All statistical analyses will be performed using SAS  (SAS 
Institute, Cary, NC 27513). 
12.4. Planned Interim Analysis and Data Safety Monitoring Committee  
No interim analysis is planned for this study. During the study, patient safety will be monitored 
on a continuous basis by the m edical m onitor until the last patient completes his or her last 
scheduled study assessment. 
An independent D MC will also be established to provide an ongoing, independent review and 
assessment of the safety data, and to safeguard the interests and  
safety of the participating patients in the study . The ongoing review of SAEs and other 
responsibilities of the DMC  will be described  in the DMC  Charter.  
 
 
Apellis Pharmaceuticals, Inc
Page 60 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
The overall T ype I (alpha) error rate for the study will be 0.05. To accommodate DMC  data 
reviews, the alpha available for efficacy hypothesis testing will be reduced by 0.0001 for each 
DMC  review . The study is expected to have 3-4 DMC  data reviews prior to the primary  analysis 
of 12-month data and 1 review afterward .  
12.5. Sample Size Calculation and Power Considerations  
Subjects will be randomized in a 2:2:1:1 ratio to receive treatment with pegcetacoplan  monthly, 
pegcetacoplan  every  other month, sham monthly, or sham eve ry other month . The annual growth 
rate in GA lesion area is expected to have a mean of 1.47, 1.70 and 2.13 mm2/year for 
pegcetacoplan  monthly, pegcetacoplan  every -other -month, and sham -pooled groups, 
respectively, as estimated from the results of a Phase 2 trial for pegcetacoplan . The standard 
deviation of the lesion growth is estimated to be 1.50 mm2 based on the same Phase 2 trial data 
or 1.25 mm2 based on natural history data.27 The following table provides an approximation of 
the study power for a sample size of 200 subject s in each group ( ie, a total enrollment of 
600 subject s) under different alpha values and standard deviations. The approximation is 
calculated using PROC POWER one- way analysis of variance, SAS 9.4. The study power is 
likely larger when utilizing the longitudinal data to model the primary endpoint. The actual study power may also vary based on the distribution of the stratification factors ( ie, lesion area at 
screening, presence of CNV in fel low eye), and site enrollment.   
Table 4:  Power to D etect a  Difference Among  3 Groups With an E qual S ize of 
200 S ubjects  
Common 
standard 
deviation (mm2) Alpha  
(2-sided)  Power for a true mean of 1.47, 1.70, and 2.13 mm2/year for 
PM, PEOM , and sham , respectively  
PM vs sham  PEOM  vs sham  Overall  
(among 3 groups) 
1.25 0.0495  > 99.9%  92.9%  99.9%  
1.25 0.0248  99.9%  88.2%  99.7%  
1.40 0.0495  99.7%  86.5%  99.3%  
1.40 0.0248  99.3%  79.4%  98.6%  
1.50 0.0495  99.2%  81.5%  98.4%  
1.50 0.0248  98.4% 73.1%  97.0%  
Abbreviations: PM = pegcetacoplan monthly;  PEOM  = pegcetacoplan every other month.  
12.6. Statistical Analysis Set s  
The safety set  will consist of all subjects who receive any amount of IP. 
The intent -to-treat (ITT) set will include all randomiz ed subjects . Subjects will be analyzed in 
the treatment arm assigned at randomization with the  2 sham treatment arms being combined 
into a single ‘control’ group.  
The modified ITT (mITT) set  will include all randomized subjects who receive at least 1 
injection of pegcetacoplan  or sham  and have baseline and at least  1 post baseline value of GA 
lesion in the study eye as assessed by FAF. 
 
 
Apellis Pharmaceuticals, Inc
Page 61 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
The per-protocol (PP) set  will include all ITT subjects who follow the protocol without any 
major deviation(s) that could i mpact the integrity of the data . A detailed description of the 
reasons for exclusion from the PP population will be included in the statistical analysis plan 
(SAP).  
12.7. Efficacy Analyses  
The primary , secondary, and exploratory efficacy analys es will be perform ed using the I TT set 
and presented by treatment group. 
12.7.1. Primary Efficacy Analysis 
The primary efficacy endpoint is the change from baseline to Month 12 in the total area of GA 
lesion(s) in eyes injected with pegcetacoplan , either monthly (PM) or every -other month 
(PEOM ), or sham injections. GA lesion area (mm2) as measured by a quantified central reading 
center based on FAF images . The primary analysis will be the comparison of pegcetacoplan , 
either monthly (PM) or every -other month ( PEOM ) versus the combined 2 sham arms ( the 2 
sham arms will be combined into a single ‘control’ group). 
The null and alternative hypotheses for the primary efficacy analysis are: 
H0: µS = µ PM   vs  H A:  µ S ≠ µ PM, and  
H0: µS = µ PEOM vs  H A:  µ S ≠ µ PEOM  
Note: here µ indicates each group’s respective mean change from baseline to Month 12 in GA 
lesion area for the comparison of the primary endpoint. 
A mixed effect model for longitudinal data will be used to analyze the change from baseline in 
GA lesion area. The model will include treatment  and presence of CNV in the fellow eye as 
fixed effects; baseline GA lesion area ( at screening) , time (in months) as a factor ; as well as the 
time × treatment interaction term. All available data up to 12 months will be included in the 
model for the primary analysis . The mean change from baseline to 12 months will be estimated 
from the model ( ie, least square [LS] mean) and compared between each of the pegcetacoplan  
arms to the sham control . For other time point of interest , LS mean change from baseline will be 
estimated and compared between treatments . Unstructured variance covariance will be used . 
For the analysis of final study data, a similar model including data up to 24 months will be used and LS means at time  points of interest will be estimated and compared between treatment.  
As indicated in an earlier section, the study is expected to have an approximately 5 DMC  data 
reviews . Allocating an alpha level of 0.0001 for each DMC  data review, the alpha level remai ns 
for the efficacy analysis at  0.0495 to maintain an overall study alpha of 0.05. 
The hypothesis testing strategy for the primary and secondary  efficacy endpoint s will be based 
on the Gate-keeping multiple testing procedures controlling for the study wide type I error strongly at 2-sided 0.0495 as follows:  
Step 1. The  mean GA lesion growth at 12 months will be compared between the PM group 
and the Control at the α level of 0.0495. If the null hypotheses of no difference between groups in this step is rejected, the testing proceeds to Step 2 and Step 3 . If it’s not rejected, 
the testing procedure stops at this step.  
 
 
Apellis Pharmaceuticals, Inc
Page 62 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Step 2. The  mean GA lesion growth at 12 months will be compared between the PEOM  
group and the Control at the α1  level . If the null hypotheses of no difference between groups 
in this step is rejected, the α1  level will be passed down to Step 3 . The actual value of α1  will 
be specified in the SAP and it will be defined to ensure an adequate power of at least 80% for 
the comparison in this step. 
Step 3. The  mean GA lesion growth at 24 months will be compared between the PM group 
and the Control at the α level of 0.0495 if the null hypotheses are rejected at both Step 1  and 
Step 2 ; or at the α level of (0.0495 – α1)  if Step 2  testing does not reject the null hypothesis. 
If the null hypothesis at this step is rejected, the α level used at this step will be passed down 
to the next step of testing. If it’s not rejected, the testing procedure stops at this step.  
Step 4. The prioritization and alpha allocation for the remaining secondary endpoints will be 
specified in the SAP.  
The following sensitivity and supportive analyses will be performed to evaluate the robustness of the results from the primary analysis method: 
• Analyses will be repeated using the mITT and PP sets  
• Primary and secondary endpoints will also be summarized with no pooling of the 2 
sham arms . The comparison for pegcetacoplan  and sham injection within each dose 
regimen (ie,  PM vs SM and PEOM  vs SEOM) will be conduct ed 
• Multiple imputation methods and  other sensitivity analys es will be explored, and 
details will be provided in the SAP 
12.7.2. Secondary  Efficacy Analysis 
The key secondary and secondary endpoints will be analyzed in the same fashion as the primary 
endpoint using mixed effect model. The binary secondary endpoints will be analyzed using Cochran -Mantel -Haenszel test stratified by the randomization stratification factors . Hypothesis 
testing for 3 key secon dary endpoints will be performed in the order specified. The SAP will 
provide more details on multiplicity adjustment and the approach for alpha spending among the endpoints.  
Key Secondary Efficacy Endpoints  
• Change from baseline in maximum monocular reading speed (study eye), as assessed 
by MNREAD or Radner Reading Charts at Month 24 (in select countries)  
• Change from baseline in FRI index score, at Month 24. 
• Change from baseline in NL-BCVA at Month 24 as assessed by ETDRS chart.  
Secondary Ef ficacy Endpoints 
• Change from baseline in LL-BCVA at Month 12 and Month 24 as assessed by 
ETDRS chart .  
• Change from baseline in LLD at Month 12 and Month 24. 
• Change from baseline at each planned assessment in the total area of GA lesion(s) in 
the study eye (in mm2) as assessed by FAF . 
 
 
Apellis Pharmaceuticals, Inc
Page 63 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
• Change from baseline in monocular critical print size (study eye), as assessed by 
MNREAD or Radner Reading Charts, at Month 12 and Month 24 (in select countries).  
• Change from baseline in the NEI VFQ -25 distance activity subscale score at Month 
12 and Month 24 (in select countries) .  
• Number of scotomatous points assessed by mesopic microperimetry for the 
evalu ation of the macular functional response.  
• Change in macular sensitivity as assessed by mesopic microperimetry for the 
evaluation of the macular functional response. 
12.7.3. Exploratory Efficacy Analysis 
Summary statistics will be provided for the following exploratory endpoints:  
• Change from baseline in NEI VFQ-25 composite score at Month 12 and Month 24.  
• Change from baseline in NEI VFQ-25 near activity subscale score at Month 12 and Month 24 (in select countries) . 
• Comparison between study eye and fellow eye in change in GA lesion size from baseline to Month 12 and Month 24.  
• Binocular maximum reading speed as assessed by MNREAD or Radner Reading 
Charts over time (in select countries) .  
• Binocular critical print size as assessed by MNREAD or Radner Reading Charts over 
time (in select countries) . 
• Relationship between genetic polymorphisms associated with AMD wi th GA 
progression and response to pegcetacoplan . 
• Incidence of new onset of subclinical CNV in the study eye.  
• Assess sensitivity and specificity of a digital re ading speed application to detect 
disease progression / regression (optional, select sites).  
• Assess sensitivity and specificity of a digital visual function application to detect 
disease progression / regression (optional, select sites).  
12.8. Safety Analyses  
Adverse events will be collected from the time of the first study drug administration until a 
subject completes the study or discontinues prematurely. Treatment -emergent adverse events are 
defined as those AEs that develop or worsen after the first dose of study medication and up to 
30 days beyond the last dose of study medication. The current version of MedDRA will be used 
to classify all AEs . Treatment -emergent adverse events will be summarized by System Organ 
Class and Preferred Term, in accordance with th e MedDRA coding dictionary. The number of 
subjects reporting each AE P referred T erm will be tabulated for all TEAEs and separately for 
those considered as related to study treatment by the investigator or designee. Number of 
 
 
Apellis Pharmaceuticals, Inc
Page 64 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
subjects reporting SAEs will also be tabulated . Adverse event summaries will be presented for 
each treatment group separately .  
Adverse events will be summarized by MedDRA coding terms, and separate tabulations also will 
be produced for related AEs (those considered by the investigator as definitively drug related), 
SAEs , and discontinuations due to AEs . Vital signs data a nd findings from physical and 
ophthalmologic examinations will be tabulated for changes over time on study. Laboratory parameters will be summarized for changes across study by using descriptive statistics. Separate 
summaries will be prepared for systemic (nonocular ) and ocular AEs, with events in the study 
eye and nonstudy eye summarized separately  
12.8.1. Anti -Therapeutic Antibodies   
Data on anti-therapeutic antibodies ( ATAs ) directed against pegcetacoplan  will be summarized 
by the number and percentage of subje cts with confirmed positive ATAs .  
12.8.2. Death   
Patient deaths and primary cause of death will be summarized .  
12.8.3. Ocular  Assessments  
Descriptive summaries will be generated for  ocular assessments, such as VA and IOP. 
12.9. Handling of Missing Data  
All efforts will be made to minimize missing data . A full description of the imputation methods 
will be provided in the SAP.  
12.10.  Visit Windows  
Analysis visits will be derived with windows for the monthly visits to assess the primary 
endpoint. Baseline is defined as the date of randomization . If 2 or more treatment visits occur 
within a window, the closest visit to the target day will be used as that analysis visit; if 2 visits are equidistant fr om the scheduled analysis visit day, the later analysis visit will be used.  
 
 
Apellis Pharmaceuticals, Inc
Page 65 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
13. ETHICS 
13.1. Ethical Conduct of the Study  
This research will be carried out in accordance with the protocol, applicable regulations, the 
ethical principles set forth in the Declaration o f Helsinki, and the ICH Harmonized Tripartite 
Guidance for Good Clinical Practice, E6 , R1 (ICH GCP).  
13.2. Institutional Review Board/Ethic Committee  
The study protocol, any amendments to the protocol, ICF , the I B, and other study- specific 
information will be re viewed and approved by the IRB/IEC. The study will not be initiated until 
the IRB/IEC  has approved the protocol or a modification thereof. All records pertaining to 
IRB/IEC submission and approval should be kept in the site’s regulatory files and sponsor’s Trial Master File.  
The IRB/IEC must be constituted and operate in accordance with the principles and requirements described in ICH Guidance E6 and national and local regulations as deemed appropriate. 
13.3. Subject Information and Consent  
The principal investigator , or designee, is responsible for obtaining an informed consent. A 
written informed consent, in compliance with ICH Guidance E6, must be obtained from each subject  at the screening visit,  prior to performing any study- related procedures.  
The purpose of the study, the procedures to be carried out, and the potential hazards will be described to the subjects in nontechnical  terms . The subject will be given sufficient time to 
consider the study’s implications before deciding to participate in the study. The  subject and/or 
legal guardian will be required to sign and date an ICF and will be assured that they may withdraw from the study at any time without jeopardizing their medical care . The PI shall retain 
the original, signed informed consent for study participation in the subject’s medical record and shall provide the subject and/or legal guardian with a copy of the signed consent. 
If there are any changes/amendments to the approved protocol, which may directly affect the 
subject’s decision to continue participation in the study, the ICF shall be amended to incorporate 
the changes to the protocol and the subject must re- sign the IRB/IEC approved amended ICF.  
 
 
Apellis Pharmaceuticals, Inc
Page 66 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
14. ADMINISTRATIVE CONSIDERATIONS  
14.1. Direct Access to Source Data/Documents  
The principal investigator , or de signee,  must maintain, at all times, the primary records (ie,  
source documents) of each subject’s data for data verification . Examples of source documents 
are medical records, laboratory reports, study drug records, and printed CRF pages that are used 
as the source.  
The investigator will permit trial- related monitoring, audits, and inspections by the sponsor 
and/or its designee, IRB/IEC, and the regulatory agencies at any time during the study. The investigator will ensure that the auditor is allowed direct access to the source data, medical 
records, eCRF s, and the site’s regulatory file for the study and any other pertinent information.  
14.2. Quality Control and Quality Assurance  
This study is to be performed in full compliance with the protocol, GCP, and applic able 
regulatory requirements. The principal inves tigator, sponsor, and/or its designee are responsible 
for ensuring that the study staff receive appropriate training on the protocol, study procedures, and any other relevant information.  
Quality assurance and quality control systems are implemented and maintained using written Investigative site, sponsor and/or designee Standard Operating Procedures (SOPs) to ensure that 
the study is conducted and data are generated, documented (recorded), and reported in 
compliance with the protocol, GCP, and the applicable regulatory requirement(s) and local laws, rules, regulations. 
Quality control checks will be applied at each stage of data handling ( eg, edit checks) to ensure 
that all data are reliable and have been processed correctly.  
14.3. Monitoring  
On-site monitoring will be performed by the sponsor’s designee for the duration of the study. 
The monitor will ensure that the study is conducted, recorded,  and reported in accordance with 
the protocol, SOPs, GCP, and the appl icable regulatory requirements . The monitor will verify the 
accuracy and completeness of the eCRF entries, source documents, and other study- related 
records against each other. The inves tigator , or designee, will provide direct access to source 
data/documents for study- related monitoring . It is important that the investigator and the 
investigator site staff are available at these visits . The monitor will record the date of each visit 
together with a summary of the status and progress of the study. Proposed actions will be 
documented in writing to the investigator. 
14.4. Data Handling and Record Keeping  
The i nvestigator must maintain all documentation related to this study . All essential documents 
(as defined in the ICH Guideline E6 and applicable local regulations ) and the data generated in 
connection with this study, together with the original copy of the final report, will be retained for at least 2 years after the last approval of a marketing application in an ICH region and until there 
 
 
Apellis Pharmaceuticals, Inc
Page 67 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
are no pending or contemplated marketing applications in an ICH region or at least 2 years have 
elapsed since the formal discontinuation of clinical development of the IP. These documents 
should be retained for a longer period if required by the applicable regulatory requirements or by 
an agreement with the sponsor. 
It is the responsibility of the sponsor to inform the investigator/ institution as to when these 
documents no longer need to be retained. 
14.5. Protocol Ame ndments  
Any amendments to the study protocol deemed necessary as the study progresses will be 
discussed between sponsor and the investigator. The investigator will not implement any changes 
to the protocol without an agreement by the s ponsor and prior review and documented 
approval/favorable opinion from the IRB/IEC of an am endment, except where necessary to 
eliminate immediate hazards to study subject or when the changes involve only logistical or 
administrative aspects of the study ( eg, change in staf f, telephone numbers).  
Changes resulting in amendments will be made jointl y between the sponsor and the investigator 
and must be confirmed in writing. Amendment(s) will be approved and signed off in the same way as the protocol.  
14.6. Report Format  
According to the ICH Harmonized Tripartite Guideline (Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use M4 and the ICH M2 Expert 
Working Group), the final report will be written according to the ICH E3 Guideline (Structure 
and Content of Clinical Study Reports). 
14.7. Finance and Insurance  
Finance and insurance will be addressed in a Clinical Trial Agreement between the s ponsor and 
the investigator/ institution . 
14.8. Publication Policy  
The data generated for this study are considered confidential information and are the property of the sponsor. All study  information provided to the PI and site personnel by the sponsor shall not 
be published or disclosed to a third party without the prior written consent of the sponsor.  
Apellis will endeavor to publish the results of all qualifying, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are perceived as positive, neutral, or negative. Additionally, Apellis ad heres to external guidelines 
(eg, Good Publication Practices 2) when forming a publica tion steering committee, which is 
done for large, multicenter Phase 2-4 and certain other studies as determined by Apellis. The purpose of the publication steering commit tee is to act as a noncommercial  body that advises or 
decides on dissemination of scientific study data in accordance with the scope of this policy. 
All publications relating to Apellis products or projects must undergo appropriate technical and 
intellectual property review, with Apellis  agreement to publish prior to release of information. 
The review is aimed at protecting the sponsor’s proprietary information existing either at the 
 
 
Apellis Pharmaceuticals, Inc
Page 68 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
commencement of the study or generated during the study. To the extent permitted by the 
publisher and copyright law, the investigator will own (or share with other authors) the copyright 
on his/her publications. To the extent that the investigator has such sol e, joint,  or shared rights, 
the investigator grants the sponsor a perpetual, irrevocable, royalty- free license to make and 
distribute copies of such publications. 
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral, or other form.  
Subject to the terms of the paragraph below, the investigator shall have the right to publish the study results, and any background information provided by the sponsor that is necessary to include in any publication of study results, or necessary for other scholars to verify such study 
results . Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writ ing by Apellis, the institution and investigator 
shall withhold submission of such publication for up to an additional 60 days to allow for filing 
of a patent application. 
If the study is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication of the compiled and analyzed study results. If such a multicenter publication is not s ubmitted to a 
journal for publication by the sponsor within an 18-month period after conclusion, abandonment, or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter study publication of the study results, an investigator may individually publish the study results 
from the specific site in accordance with this section . The investigator must, however, 
acknowledge in the publication the limitations of the single- site data being presented.  
Unless otherwise required by the journal in which the publication appears, or the forum in which it is made, authorship will comply with the International Committee of Medical Journal Editors 
current standards . Participation as an investigator does not confer any rights to authorship of 
publications. 
14.9. ClinicalTrials.gov  
This study wi ll be listed with ClinicalTrials.gov.  
14.10.  Termination of Study  
The sponsor reserves the right to suspend or discontinue this study for administrative and/or safety reasons at any time. The investigator reserves the right to discontinue dosing subjects at 
any t ime for safety reasons .  
 
 
 
Apellis Pharmaceuticals, Inc
Page 69 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
15. REFERENCES 
1. Holz FG, Bindewald-Wittich A, Fleckenstein M, et al . Progression of geographic atrophy and 
impact of fundus autofluorescence patterns in  age- related macular degeneration . American 
journal of ophthalmology. 2007;143(3): 463-472. 
2. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through 
the year 2050: the potential impact of new treatments . Archives of ophthalmology . 
2009;127(4):533-540. 
3. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalen ce of age-related macular degeneration in 
the United States . Archives of ophthalmology . 2004;122(4):564-572. 
4. Holz FG, Strauss EC, Schmitz -Valckenberg S, van Lookeren Campagne M . Geographic atrophy: 
clinical features and potential therapeutic approaches . Ophthalmology. 2014;121(5):1079-1091. 
5. Sunness JS, Bressler NM, Tian Y, Alexander J, Applegate CA. Measuring geographic atrophy in 
advanced age- related macular degeneration. Investigative ophthalmology & visual science. 
1999;40(8):1761-1769. 
6. Sunness JS, Gonza lez-Baron J, Applegate CA, et al. Enlargement of atrophy and visual acuity 
loss in the geographic atrophy form of age- related macular degeneration . Ophthalmo logy. 
1999;106(9):1768-1779. 
7. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach  to the etiology of age -
related macular degeneration . Proceedings of the National Academy o f Sciences of the United 
States of America . 2002;99(23):14682-14687. 
8. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement 
regulatory gene  factor H (HF1/CFH) predisposes individuals to age- related macular degeneration . 
Proceedings of the National Academy of Sciences of the United States of America . 
2005;102(20):7227-7232. 
9. Lommatzsch A, Hermans P, Muller KD, Bornfeld N, Bird AC, Pauleikhoff D. Are low 
inflammatory reactions involved in exudative age -related macular degeneration? Morphological 
and immunhistochemical analysis of AMD associated with  basal deposits. Graefe's archive for 
clinical and experimental ophthalmology = Albrecht von Graefe s Archiv fur klinische und 
experimentelle Ophthalmologie . 2008;246(6):803-810. 
10. Mullins RF, Russell SR, Anderson DH, Hageman GS . Drusen associated with aging and age-
related macular degeneration contain proteins common to extracellular deposits associated w ith 
atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB journal : official 
publication of the Federation of American Societies fo r Experimental Biology . 2000;14(7):835-
846. 
11. Edwards AO, Ritter R, 3rd, Abel KJ, Manning A, Panhuysen C, F arrer LA . Complement factor H 
polymorphism and age -related macular degeneration . Science. 2005;308(5720):421-424. 
12. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-
related macular degeneration . Science . 2005;308(5720):419-421. 
 
 
Apellis Pharmaceuticals, Inc
Page 70 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
13. Klein RJ, Zeiss C, Chew EY, et al . Complement factor H polymorphism in age- related macular 
degeneration. Science. 2005;308(5720):385-389. 
14. Maller J, George S, Purcell S, et al . Common variation in three genes, including a noncoding 
variant in  CFH, strongly influences risk of age- related macular degeneration . Nature genetics. 
2006;38(9):1055-1059. 
15. Seddon JM, Yu Y, Mille r EC, et al . Rare variants in CFI, C3 and C9 are associated with high risk 
of advanced age- related macular degeneration . Nature  genetics. 2013;45(11):1366-1370. 
16. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age- related macular 
degeneration. The New England journal of medicine. 2007;357(6):553-561. 
17. van de Ven JP, Nilsson SC, Tan PL, et al. A functional variant in the CFI gene confers a high risk 
of age -related macular degeneration . Nature genetics. 2013;45(7):813-817. 
18. Fritsche LG, Chen W, Schu M, et al . Seven new loci associated with age- related macular 
degeneration. Nature genetics. 2013;45(4):433-439, 439e431-432. 
19. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 
(C2) genes is associated with age- related macular degeneration . Nature genetics. 2006;38(4):458-
462. 
20. Horie -Inoue K, Inoue S. Genomic aspects of age- related macular degeneration . Biochemical and 
biophysical research communications . 2014;452(2):263-275. 
21. Hecker LA, Edwards AO . Genetic control of complement activation in humans and age related 
macular degeneration . Advances in experimental medicine and biology. 2010;703:49-62. 
22. Hecker LA, Edwards AO, Ryu E, et al. Genetic control of the alternative pathway of complement 
in humans and age- related macular degeneration . Human molecular genetics. 2010;19(1):209-
215. 
23. Machalinska A, Dziedziejko V, Mozolewska-Piotrow ska K, Karczewicz D, Wiszniewska B, 
Machalinski B . Elevated plasma levels of C3a complement compound in the exudative form of 
age-related macular degeneration . Ophthalmic research . 2009;42(1):54-59. 
24. Scholl HP, Charbel Issa P, Walier M, et al . Systemic comp lement activation in age -related 
macular degeneration . PloS one. 2008;3(7):e2593. 
25. Leeds JM, Henry SP, Bistner S, Scherrill S, Williams K, Levin AA . Pharmacokinetics of an 
antisense oligonucleotide injected intravitreally in monkeys. Dru g metabolism and disposition: 
the biological fate of chemicals . 1998;26(7):670-675.  
26. Fleckenstein  M, Mitchell P, Freund KB , et al. The Progression of Geographic Atrophy Secondary 
to Age- Related Macular Degeneration . Ophthalmology . 2018; 125(3):369-390. 
 
 
Apellis Pharmaceuticals, Inc
Page 71 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
G. Only subjects that sign the separate consen t for the clinical repository  and genotyping will have these samples collected . A 14-mL whole -blood sample will be collected at each 
of the specified visits . 
H. Blood pressure, respiratory rate, hea rt rate, and temperature. On dosing days, vital signs should be taken pre dose. 
I. Height and weight  should be collected  at screening.  
J. Perform assessments prior to dilating the eyes.  
K. In select countries , the MNREAD or Radner Reading  Charts should be done during the study visit, prior to dilating the eyes . It should be performed monocularly first, then 
binocularly.  
L. Microperimetry assessments will be performed post  dilation . Data will be forwarded to the reading center.  
M. To be administered by the masked site staff prior to any other assessments performed on that day . In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating the eyes. 
N. At select sites,  and for those subjects who decide to participate,  the digital application s will be completed on an electronic device and will consist of assessments for visual 
function and reading speed. Subjects will receive training at Day 1 on the use of the digital applications and the electronic device and will perform the tests using the application 
in the clinic at Month 1, Month 2, Month 3, Month 6, Month 12, Month 18, and  Month 24 . Beginning at Day  1, subjects will complete the functional assessments weekly at 
home. Subjects should be instructed to complete the assessments on the same day each week and at approximately the same time of day  each week, if possible.  
O. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs w ill be performed for the study eye only on days where 'SE' is specified 
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for specifics on 
image capture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next schedul ed visit. If new active CNV is suspected, SD-OCT , FFA and OCT -A (select sites) images 
must be collected and sent to the r eading center for analysis.  
P. Postinjection assessments should be performed within 5 minutes after dosing by the unmasked physician or  study staff and should include a gross assessment of vision (finger -
counting, hand-motion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry 
shoul d be performed . IOP should be ≤ 30 mm Hg  in order for the subject to leave the site . If necessary, anti glaucomatous  medication can be given to lower the  IOP. If IOP is  
>30 mm Hg, assessments will continue every approximately 3 0 minutes from the previous measurement until the subject passes gross vision test and IOP is ≤30 mm Hg. Note: if 
the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab or 
aflibercept mus t be performed first . The pre - and  post - anti-VEGF IOP val ues must be measured and recorded on the eCRF.  
Q. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 3) to col lect any information on any 
safety concerns, decrease in vi sion, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as possible.  
R. Record concomitant medications ( ie, prescripti on and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in 
the study.  
S. In addition to the time points indicated on the stud y schedule,  OCT -A should be performed at the time of any suspected new active CNV . If new active CNV  is confirmed  in the 
study eye , OCT -A should be repeated every 2 months  for the study eye . 
T. Administration of pegcetacoplan  or sham  can be done on separate days from  the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If this occurs on the r andomizatio n visit, then the 
administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the m edical monitor . When study treatment administration is on 
a day other than  a study visit, then the only assessm ent that mu st be done on the day of study treatment administration is pre injection  IOP. 
 
 
Apellis Pharmaceuticals, Inc
Page 74 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
I. Height and weight  should be measured at screening.  
J. Perform assessments prior to dilating the eyes.  
K. In select countries , the MNREAD or Radner Reading  Charts should be done during the study visit, prior to dilating the eyes . It should be performed monocularly first, then 
binocularly.  
L. Microperimetry  assessments will be performed post  dilation . Data will be forwarded to the reading center.  
M. To be administered by the masked site staff prior to any other assessments performed on that day . In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating the eyes. 
N. At select sites, and for those subjects who decide to participate, t he digital application s will be completed on an electronic device and will consis t of assessments for visual 
function and reading speed. Subjects will receive training at D ay1 on the use of the digital applications and the electronic device and will perform the tests using the applic ation 
in the clinic at Month  1, Month 2, Month 3, Month 6, Month 12, Month 18, and  Month 24 . Beginning at Day  1, subjects will complete the functional assessments weekly at 
home . Subjects should be instructed to complete the assessments on the same day each week and at approximately the same time of day each  week, if possible .  
O. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for specifics on 
image capture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit . If new active CNV is suspected, SD-OCT , FFA , and OCT -A (selected sites)  
images should be collected and sent to the reading center for analysis.  
P. Postinjection assessments should be performed within 5 minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand motion, then light perception when applicabl e). If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry  
should be performed . IOP should be ≤30 mm Hg in order for the subject to leave the site . If necessary, anti glaucomatous  medication can be given to lower the IOP . If IOP is 
>30 mm Hg, assessments will continue every approximately 3 0 minutes from the previous measurement until the subject passes gross vision test and IOP is ≤ 30 mm Hg. Note: if 
the study eye is treated with a  ranibizumab o r aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab or 
aflibercept must be performed first . The pre - and post - anti-VEGF IOP values must be measured and recorded on the eCRF. 
Q. Start ing at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 3) to collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocula r symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as possible.  
R. Record concomitant medications ( ie, prescription and over -the-counter medications) used by the patien t within 30 days of screening and throughout the subject's participation in 
the study .  
S. In addition to the time points indicated on the study schedule,  OCT -A should be performed at the time of any suspected new active CNV . If new active CNV  is confirmed  in the 
study eye , OCT -A should be repeated every 2 months  for the  study  eye.  
T. Administration of pegcetacoplan  or sham can be done on separate days from the assessment visit if both days fall within the visit window . Admin istration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If this occurs on the randomization visit, then the 
administration of pegcetacoplan  or sham should be done within 3 days of randomizati on and after approval from the m edical monitor . When study treatment administration is on 
a day other than a study visit,  then the only assessment that must be done on the day of study treatment administration is pre injection  IOP. 
 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 77 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
J. Perform asses sments prior to dilating the eyes.  
K. In select countries , the MNREAD or Radner Reading  Charts should be done during the study visit, prior to dilating the eyes . It should be performed monocularly first, then 
binocularly.  
L. Microperimetry assessments will  be performed post  dilation . Data will be forwarded to the reading center.  
M. To be administered by the masked  site staff prior to any other assessments performed on that day . In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating the eyes. 
N. At select sites,  and for those subjects who decide to participate,  the digital application will be completed on an electronic device and will consist of assessments for visual 
function and reading speed. Subjects will receive training at Day 1 on the use of the digital applic ations and the electronic device and will perform the tests using the application 
in the clinic at Month 1, Month 2, Month 3, Month 6, Month 12, Month 18, and Month 24 . Beginning at Day  1, subjects will complete the functional assessments weekly at 
home . Subjects should be instructed to complete the assessments on the same day each week and at approximately the same time of day each week, if po ssible .  
O. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs will b e performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for specifics on 
image cap ture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit. If new active CNV is suspected, SD-OCT , FFA , and OCT -A (selected sites)  
images should be collected and sent to the reading center for analysis.  
P. Postinjection assessments should be performed within 5 minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry  
should be performed . IOP should be ≤ 30 mm Hg  in order for the subject to leave the site. If necessary, antiglaucomatous medication can be given to lower the IOP. If IOP is 
>30 mm Hg, assessments will continue every approximately 3 0 minutes from the previous measurement until the subject passes gross vision test and IOP is ≤30 mm Hg. Note: if 
the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab or  
aflibercept must be performed first . The pre - and post - anti-VEGF IOP valu es must be measured and recorded on the eCRF . 
Q. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 4) to collect any information on any 
safety concerns, decrease in vis ion, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as possible.  
R. Record concomitant medications ( ie, prescriptio n and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in 
the study .  
S. In addition to the time points indic ated on the study schedule,  OCT -A should be performed at the time of any suspected new active CNV . If new active CNV  is confirmed  in the 
study eye , OCT -A should be repeated every 2 months  for the study eye. 
 T. Administration of pegcetacoplan  or sham can b e done on separate days from the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If thi s occurs on the randomizati on visit, then the 
administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the m edical monitor . When study treatment administration is on 
a day other than a study visit, then the only assessment that mu st be done on the day of study treatment administration is pre injection  IOP. 
  
 
 
Apellis Pharmaceuticals, Inc
Page 80 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
I. Height and weight  should be measured at screening .  
J. Perform assessments prior to dilating the eyes.  
K. In select countries , the MNREAD or Radner Reading  Charts should be done during the study visit, prior to dilating the eyes . It should be performed monocularly first, then 
binocularly.  
L. Microperimetry assessments will be performed post  dilation . Data will be forwarded to the reading center. 
M. To be administered by the masked site staff prior to any other assessments performed on that day . In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to d ilating the eyes . 
N. At select  sites, and for those subjects who decide to participate, t he digital applicatio ns will be completed on an electronic device and will consist of assessments for visual 
function and reading speed. Subjects will receive training at Day  1 on the use of the digital applications and the electronic device and will perform the tests using the application 
in the clinic at Month 1, Month 2, Month 3, Month 6, Month 12, Month 18, and Month 24 . Beginning at Day  1, subjects will complete the functional assessments weekly at 
home . Subjects should be instructed to complete the assessments on the same d ay each week and at approximately the same time of day each week, if possible.   
O. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for specifics on 
image capture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit . If new active CNV is suspected, SD -OCT , FFA , and OCT -A (selecte d sites)  
images should be collected and sent to the reading center for analysis.  
P. Postinjection assessments should be performed within 5 minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (fing er-
counting, hand motion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry  
should be performed . IOP should be ≤ 30 mm Hg in order for the subj ect to leave the site. If necessary, antiglaucomatous medication can be given to lower the IOP. If IOP is 
>30 mm Hg, assessments will continue every approximately 3 0 minutes from the previous measurement until the subject passes the gross vision test and I OP is ≤30 mm Hg. 
Note: if the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab 
or aflibercept must be performed first . The pre - and post - anti-VEGF IOP values must be measured and recorded on the eCRF . 
Q. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 4) to collect any information on any 
safety concerns, dec rease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the investigator determines that there are any safety 
concerns, a follow -up visit should be scheduled as soon as possible.  
R. Record concomitant medications ( ie, prescription and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in 
the study .  
S. In addition to the time points indicated on the study schedule,  OCT -A should be perf ormed at the time of any suspected new active CNV . If new active CNV  is confirmed  in the 
study eye , OCT -A should be repeated every 2 months  for the study eye.  
T. Administration of pegcetacoplan  or sham  can be done on separate days from the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If this occurs on the randomization visit, then the 
administration  of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the m edical monitor . When study treatment administration is on 
a day other than a study visit,  then the only assessment that must be done on the day of study tr eatment administration is preinjection  IOP. 
 
 
Apellis Pharmaceuticals, Inc
Page 83 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
APPENDIX E: NATIONAL EYE INSTITUTE VISUAL FUNCTIONING 
QUESTIONNAIRE 25- ITEM VERSION  
  
 
 
Apellis Pharmaceuticals, Inc
Page 84 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 85 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 86 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 87 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 88 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
 
Apellis Pharmaceuticals, Inc
Page 89 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 90 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 91 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 92 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 93 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 94 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 95 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 96 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 97 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 98 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 99 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 100 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
APPENDIX F: FUNCTIONAL READING  INDEPENDENCE INDEX (FRI)  
Kimel M, Yu R, Leidy N. The Functional Reading Independence Index (FRI Index) - User Manual 
(Version 1.2). Evidera . 2015  
  
 
 
Apellis Pharmaceuticals, Inc
Page 101 of 164
Confidential
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 103 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 104 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 105 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 106 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 107 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 108 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 109 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 110 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 111 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 112 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 113 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 114 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 115 of 164
Confidential
CCI
 
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 116 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 117 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 118 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 119 of 164
Confidential
CCI
 
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 120 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 121 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 122 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 123 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 124 of 164
Confidential
CCI
 
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 125 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 126 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 127 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 128 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 129 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 130 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 131 of 164
Confidential
CCI
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 132 of 164
Confidential
CCI
 
Pegaetacoplan 
APL2-304 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 133 of 164
Confidential
CCI
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
APPENDIX G: MINNESOTA LOW-VISION READING TEST (MNREAD)  
AND RADNER READING CARDS      
The manual of procedures should be referenced for a detailed table of countries and languages to 
determine which test will be administered . Equipment and testing procedures will also be 
described in detail in the manua l of procedures for both tests.  
Minnesota Low-Vision Reading Test: 
The Minnesota Low- Vision  Reading Test acuity cards are continuous- text reading -acuity cards 
used for measuri ng the reading acuity and speed of normal and low-vision patients. These charts 
were developed at the Minnes ota Laboratory for Low-Vision Research, University of Minnesota, 
Minneapolis, Minnesota, USA.  
The MNREAD Acuity Charts will be used to measure:  
• Critical Print Size: the smallest print that the patient can read with maximum speed  
• Maximum Reading Speed: the patient’s reading speed when reading is not limited by 
print size  
Radner Reading Cards:  
The Radner Reading Cards consist of sentence optotypes, which are optimized reading test items, standardized by construction and statistical selection . These cards  allow for accurate and 
comparable measurements of reading acuity  and reading speed and measurement of critical print 
size. 
 
 
 
Apellis Pharmaceuticals, Inc
Page 134 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
APPENDIX H: GRADING SCALE FOR  ASSESSMENT OF ANTERIOR 
CHAMBER FLARE OR CELLS  
AQUEOUS REACTION—FLARE  
Grade  Description  
0 No protein is visible in the anterior chamber when viewed by an experienced observer 
using slit lamp  biomicroscopy; a small, bright, focal slit-beam of white light; and high 
magnification.  
Trace  Trace amount of protein detectable in the anterior chamber . This prote in is visible only 
with careful scrutiny by an experienced observer using slit lamp  biomicroscopy; a small, 
bright, focal slit -beam of white light; and high magnification.  
1+ Mild amount of protein detectable in the anterior chamber. This protein is immediately apparent to an experienced observer using slit lamp  biomicro scopy and high magnification, 
but such protein is detected only with careful observation with the naked eye and a small, bright, focal slit -beam of white light. Note presence of any fib rin. 
2-3+ Moderate amount of protein detectable in the anterior chamber. These grades are similar to 1+ but the opacity would be readily visible to the naked eye of an observer using any source of a focused beam of white light. This is a continuum of moderate opacification, with 2+ being less apparent than 3+. Note presence of any fibrin.  
4+ A large (severe) amount of protein is detectable in the anterior chamber . Similar to 3+, but 
the density of the protein approaches that of the lens. Additionally, frank fibrin deposition is frequently seen in acute circumstances . It need s to be noted that because fibrin may 
persist for a period of time after partial or complete restoration of the blood -aqueous 
barrier, it is possible to have resorbing fibrin present with lower numeric assignations for 
flare (eg, 1+ flare with fibrin).  
 
AQUEOUS REACTION—CELLS  
Grade  Description  
0 No cells are seen in any optical section when a large slitlamp  beam is swept across the 
anterior chamber.  
Trace  Rare (1 -3) cells are observed when the slit lamp  beam is swept across the anterior chamber . 
When the instrument is held stationary, not every optical section contains circulating cells.  
1+ 3-10 cells/optical section are seen when the slit lamp  beam is swept across the anterior 
chamber . When the instrument is held stationary, every optical section contains circulating 
cells. Note stage of hypopyon, if applicable.  
2+ 10-25 cells are seen when the slit lamp  beam is swept across the anterior chamber. When 
the instrument is held stationary, every optical section contains circulating cells . Note 
stage of hypopyon, if applicable.  
3+ 25-50 cells are seen when the slit lamp  beam is swept across the anterior chamber. When 
the instrument is held stationary, every optical section contains circulating cells . Keratic 
precipitates or cellular deposits on the anterior lens capsule may be present . Note stage of 
hypopyon, if applicab le. 
4+ More than 50 cells are seen when the slit lamp  beam is swept across the anterior chamber. 
When the instrument is held stationary, every optical section contains circulating cells or 
 
 
Apellis Pharmaceuticals, Inc
Page 135 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
hypopyo n is noted . As for the fibrin deposition, hypopyon may persi st for a period of time 
after exudation of cells into the anterior chamber has diminished or ceased entirely, 
making it possible for have 1+ circulating cells in the anterior chamber with a resolv ing 
hypopyon. 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 136 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
APPENDIX I: GRADING SCALE FOR ASSESSMENT  OF VITREOUS 
CELLS  
Grade  Description  Cells in Retro -Illuminated Field  
0 Clear  0 
Trace  Few opacities  1-20 
1 Scattered opacities  21-50 
2 Moderate opacities  51-100 
3 Many opacities  101-250 
4 Dense opacities  ≥ 251  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 137 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Section revi
sed to further define approved methods of contraception 
include:  
• Combined (estrogen- and progestogen- containing) hormonal 
contraception associated with inhibition of ovulation:  
o Oral 
o Intravaginal  
o Transdermal  
• Progestogen- only hormonal contraception associated with 
inhibition of ovulation:  
o Oral 
o Injectable  
o Implantable  
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
• Vasectomized partner (provided that partner is the sole sexual 
partner of the WOCBP trial participant and that the 
vasectomized partner has received medical assessment of the 
surgical success)  
• Sexual abstinence (defined as refraining from heterosexual 
intercourse during the entire period of risk associated  with the 
study treatments) . Sexual abstinence is only accepted when it is 
the preferred and usual lifestyle of the subject.  
Approved methods of contraception include: oral contraceptives, 
intrauterine device, medically acceptable barrier methods 
(diaphragm or condom), implantable or injectable contraceptives 
(like DepoProvera) or removable birth control device (like 
NuvaRing or Ortho Evra patches); and/or surgical sterilization (at 
least 6 months before dosing) . Subjects practicing abstinence and 
coitus in terruptus (pull out method) must agree to use an approved 
method of contraception during the study and 90 days after their last 
dose of study drug.  Section  6.4  Approved Methods of 
Contraception  
The following section was added:  
 
A subject may withdraw from the study at  any time for any reason 
without prejudice to his/her future medical care by the physician or at the 
institution . The investigator or sponsor may withdraw the subject at any 
time (e.g., in the interest of subject safety) . The inve stigator is 
encouraged to discuss withdrawal of a subject from treatment with the 
investigational product with the m edical monitor when possible.  
Subjects who discontinue treatment with the investigational product can 
continue participation in the study and should be encouraged  to return to 
the clinical site for as many follow -up visits as they can. In the event that 
a subject terminates early from the study, all early termination 
procedures should be performed even if they are outside the allowed 
study window .  
The reason for term ination, date of stopping treatment with 
investigational product, all follow -up information and the total amount of 
investigational product administered must be recorded in the case report 
form (CRF) and source documents.  Section  6.5  Discontinuation of 
Subjects  
 
 
Apellis Pharmaceuticals, Inc
Page 139 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
 
 
The requirement to notify the sponsor prior to unmasking was removed:  
 
In the event of a medical emergency where the knowledge of subject 
treatment by masked individuals (e.g., the subject or his/her physician) i s 
required, an individual Investigator (or designee) will have the ability to unmask the treatment assignment for a specific subject and share that 
information with the appropriate parties . The Investigator (or designee) 
must endeavor to notify the Sponsor  prior to unmasking a subject .  Section  7.2.1  Unmasking  
Section was revised to allow study treatment administration to occur on a 
day separate from the assessment visit:  
 
Section was revised to allow study treatment administration to occur on a 
day separate from the assessment visit:  
 
Only qualified study staff and those delegated the responsibility of study 
drug administration on the Delegation of Authority log should perform 
this procedure . All staff should be appropriately trained on all procedures 
prior to performing the procedures . Sites should follow the Visit 
Schedule for order of procedures and assessments .  
Administration of study treatment (APL -2 or Sham) can be done on a 
separate day from the assessment visit if both days fall within the visit 
window . If this occurs on the randomization visit, then the administration 
of APL -2 or Sham should be done within 3 days of randomization and 
after approval from the m edical monitor . When study treatment 
administration is on a day other than  a study visit, then the only 
assessment that mus t be done on the day of study treatment 
administration is the pre -injection IOP .  
If a subject falls outside the visit window for a dosing visit, the dose 
should be skipped and the subject should be scheduled on time for the 
next dosing visit.  Section  7.3.2  Treatment 
Administration  
The description of sham injection was modified as there is no 
requirement for sham to be sterile:  
 
Sham will be provided as sterile  empty stoppered glass vials and should 
be stored according to the label .   
 Section  7.3.3.1 Ide ntity of the 
Investigational Product  
The procedure for sham injection was further described:  
 
The procedure for sham injection will be the same as that used for IVT 
injection until the actual injection but no actual injection will occur. The 
injecting phy sician will only touch the study eye with the blunt end of 
the syringe . No needle or medication will be injected inside the eye . Section  7.4  Sham Injection 
Administration  
 
 
Apellis Pharmaceuticals, Inc
Page 140 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Detailed instructions on sham injection procedures and post -injection 
procedures will be provided in the Manual of Procedures.  
 
The end of the trial for each subject was defined:  
 
The end of the trial for each subject is defined as when the subject either 
completes their Mont h 24 Visit and enrolls in the open- label extension 
study or, should a subject elect not to enter the open label  extension 
study, when the subject completes their exit visit at Month 30.  
 
Through the section it has also been noted that endothelial cell count 
assessment is for “select sites only”. This was previously no ted in the 
schedule of events but not consistently in the body of the protocol . In 
addition FAF and NAR are no longer “study eye only”.  
 Section  8  Study Procedures  
The fo llowing assessments were removed as they will no longer be 
conducted at the screenin g Visit 1: 
• Low luminance BCVA  
• Endothelial cell count  
• OCT A 
The following text was moved to Section  8.1.2 as training for home -
based digital applications will now be conducted at Visit 2: 
Prior to dilating the eyes, subjects at select sites will be trained on how to 
use the home based digital applications for visual function and reading 
speed if the subje ct decides to participate in this portion . This training 
must occur after completion of all functional tests (NL BCVA, LL
BCVA).  Section  8.1.1  Visit  1 All Subjects  
It was clarified that:  
All assessments should be performed on the same day. All study visits 
should be scheduled and projected based on the Day  1 visit.  
 
The following text was added as home -based digital application training 
will now occur at Vi sit 2: 
Subjects at select sites will be trained on how to use the home -based 
digital a pplications for visual function and reading speed if the subject 
decides to participate in this portion . This training must occur after 
completion of all functional tests  (NL-BCVA, LL -BCVA).  
 The following assessments were added:  
• Endothelial cell count  
• OCT -A (select sites)  
 
The following text was removed as subject discontinuation is now 
covered in Section  6.5. 
In the event that a subject is early terminated from the study , all early 
termination procedures should be performed even if they are outsi de the 
allowed study window .  
If the subject would like to discontinue dosing but is amenable to Section  8.1.2 Randomization/Init ial 
Treatment —Day —Within 28 Days 
of Screening  
 
 
Apellis Pharmaceuticals, Inc
Page 141 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
continuing in the study, the site should make every effort to have the 
subject complete as many follow up visits as possible.  
 
It has been noted in the text which assessments will be conducted at 
Month 27 and Month 30.  Section  8.1.4 Follow -up Phase  
Instructi ons were revised to include the following:  
 
All AEs encountered during the study will be monitored and reported in 
detail in the source documents and documented on the eCRF, from 
signing of the ICF until the Exit Visit. AEs should be recorded by 
maximum se verity . AEs, especially those for which the relationship to 
test drug  study treatment are considered by the Investigator to be 
possibly or definitely  related, should be followed up until they have 
returned to the baseline status or stabilized . If a clear explanat ion is 
established, it should be recorded on the eCRF.  Section  11.2   Recording Adverse 
Events  
Instructions modified as follows:  
If any AEs are serious, special procedures will be followed. All SAEs 
will be reported to the Safety Monitor by the Investigator via fax or 
email within one calendar day of becoming aware of the event, whether 
or not the serious events are deemed drug related . SAE reporting contact 
information will be provided separately and as included in the Safety 
Monitoring Plan. All SAEs must be reported to the applicable ethics 
committee by the Investigator in accordance with their regulations.  
 
Special procedures will be followed for reporting SAEs . All SAEs 
will be reported to the Safety Monitor by the Investigator via eCRF or 
fax/email (if eCRF is not available)  within 24 hours  of becoming aware 
of the event, whether or not the event is deemed treatment -related . If the 
EDC system is not operational, the site must complete the appropriate 
paper SAE form and fax/email to the number listed o n the SAE form, 
also within 24 hours of becoming aware of the event . The reported 
information submitted as a paper SAE form must be entered into the 
EDC system once it becomes operational.  
SAE reporting contact information will be provided separately and 
included in the Safety Monitoring Plan. All SAEs must be reported to the 
applicable ethics committee by the Investigator in accordance with their 
regulations.  Section  11.5 Serious Adverse Events  
The following text was added:  
A suspected adverse reaction means any AE for which there is a 
reasonable possibility that the drug caused the AE . Reasonable 
possibility means there is evidence (such as a temporal relationship) to 
suggest a causal relationship between the drug and the AE.  Section  11.6 Unexp ected Adverse 
Events or Unexpected Suspected 
Adverse Reactions  
The analysis description was modified as follows as this will be 
conducted at all sites . This is an error correction.  
• Change from baseline at each planned assessment in the total area of 
GA les ion(s) in the study eye (in mm2) as assessed by FAF (in select 
sites)   Section  12.7.2 Secondary Efficacy 
Analysis  
 
 
Apellis Pharmaceuticals, Inc
Page 142 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
Section  12.10 was added to describe how visit windows will be used  in 
the assessment of the primary endpoint:  
 
Analysis visits will be derive d with windows for the monthly visits to 
assess the primary endpoint . Baseline is defined as the date of 
randomization . If 2 or more treatment visits occur within a window, the 
closest visit to the target day will be used as that analysis visit; if 2 visits 
are equidistant from the scheduled analysis visit day, the later analysis 
visit will be used.  Section  12.10 Visit Windows  
All study schedules were modified to align with the changes noted 
above, including removal of PK and complement profile study 
assessments.  Appendix A, B, C, and D:  Visit 
Schedules  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 143 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
associated with inhibition of ovulation,  oral contraceptives,  intrauterine 
device, intrauterine hormon ereleasing system; and/or bilateral tubal 
occlusion (at least 6 months before dosing)  medically acceptable barrier 
methods (diaphragm or condom), implantable or injectable 
contraceptives (like DepoProvera) or removable birth control  device (like 
NuvaRing or Ortho Evra patches); and/or surgical sterilization (at least 6 
months before dosing) . Subjects practicing abstinence and coitus 
interruptus (pull out method) must agree to use an approved method of 
contraception during the study a nd 60 90 days after their last dose of 
study drug.  
Masking language was modified to indicate that the PI is required to 
remain masked to subjects’ treatment assignments, while the treating physician and any associated support staff involved in IP administration 
will be unmasked.  Section  7.2 Masking and 
Minimization of Bias  
Guidance on the treatment of new exudation related to  active choroidal 
neovascularization in the study eye and/or fellow eye was modified t o 
clarify that the reading center will provide a report to indicate whether or 
not there is evidence of active, exudative AMD, and the Investigator will 
then determine if  anti-VEGF treatment should be initiated . The 
Investigator should wait for the reading center report before making a 
decision regarding treatment, except in cases where there is clear evidence of disease activity that may have a detrimental visual impact i f 
not treated immediately.  
 It was also clarified that either ranibizumab or afliberce pt should be 
selected as the anti -VEGF therapy, and that the unmasked physician 
should administer anti -VEGF treatment if the treatment is administered 
on the same day as APL -2.  
 
It was also noted that any treatments of therapies administered to the 
fellow  eye within 5 years of screening should be recorded as a 
concomitant medication . Section  7.5.1 Treatment of New 
Exudation Related to Active 
Choroidal Neovascularization in the 
Study Eye and/or Fellow Eye  
Visit Schedules A -D 
The following instruction regar ding electronic devices was added:  
The subject will be instructed to bring back the electronic device for the 
visits specified in the schedule of events.  Section  8.1.3.1 Months 1 -12 
Month 6 and Month 12 were added as times of in -clinic assessment.  
It was noted that subjects will take electronic devices home at Day  1 
instead of at Screening.  Section  9.12 Home -Based 
Functional Digital Applications (in select sites/countries)  
Visit Schedules A -D. 
Clarified that:  
In the event that a subject is suspected to ha ve new active CNV in the 
study eye and/or the fellow eye, an SD -OCT and FA using the protocol 
specified procedures should be performed and sent to the Reading Center  
to confirm the diagnosis . In addition, in selected sites, OCT -A should 
also be captured according to the study imaging protocol and sent to the 
Reading Center .  Section  9.14 Ocular Imaging  
It was clarified that if the subject does not pass the gross vision test, IOP 
must be measured at that time. Additional IOP measurement must be 
taken approximately every 3 0 minutes thereafter until IOP ≤ 3 0 mm Hg Section  9.15 Post -Injection 
Assessment; Visit Schedule 
Footnote “O” (all Visit Schedules ) 
 
 
Apellis Pharmaceuticals, Inc
Page 145 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
and the subject is able to be released from the clinic.  
It was clarified that anti- VEGF treatment will be either ranibizumab or 
aflibercept, and that IOP should be measured before and after the anti -
VEGF injection, but prior to administration of APL -2. 
Blood volume for study assessments was updated based on the lab 
manual.  Section  9.16 Blood Volume for 
Study Assessments  
It was cla rified that 1514 mL whole blood sample will be collected at the 
specified time  points  for research samples. Section  9.17.2 Sample Collection  
Visit Schedules A -D 
The screening urine pregnancy test was removed  as a serum pregnancy 
test will be performed for  screening . 
 
Footnotes “M” (All Visit Schedules) was modified to indicate that 
“Beginning at Day  1 Screening, subjects will complete the functional 
assessments weekly at home.”  Visit Schedules A and C  
 
Week  24 blood draw for clinical repository was added (error correc tion).  
 Visit Schedule C  
The full version of the NEI VFQ -25 has been included in Appendix E.  Appendix E.  
An amendment history appendix was added to show changes enacted by 
previous amendments.  Appendix J  
  
 
 
Apellis Pharmaceuticals, Inc
Page 146 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
“Endothelial cell count” was removed as an assessment that will be 
provided to the reading center for objective assessment of subject 
eligibility . 
 
“Optical Coherence Tomography Angiography (OCT -A, selected sites 
only)” was added as an assessment that will be provided to the reading 
center for objective assessment of subject eligibility .  Section  7.1 Alloca tion to Treatment  
Section  8.1. Study Visit Schedule  
Section  8.1.2 Randomization/Initial 
Treatment  
“Country” and “microperimetry eligibility (yes; no) ” were removed as a 
stratification factor.  Section  7.1 Allocation to Treatment  
 
References to “DSMB” upda ted to “DMC”.  Section  7.2.1 Unmasking  
Section  10.1 Data Monitoring 
Committee  
Reference to preparing APL -2 for injection was removed from the 
paragraph describing sham.  Section  7.3.3.1 Identity of the 
Investigational Product  
Text was updated to indicate t hat:  
 
The suspected onset or presence of new active choroidal 
neovascularization (CNV) secondary to AMD in the study eye and/or 
fellow eye  must be documented in the source document and CRF .  Section  7.5.1 Treatment of New 
Active Choroidal 
Neovascularizati on in the Study Eye 
and/or Fellow Eye  
Section  9.15 Ocular Imaging  
Optical Coherence Tomography Angiography (OCT -A) was added as a 
monitoring assessment for  select sites  to confirm the diagnosis of new  
active CNV . Section  7.5.1 Treatment of New 
Active Chor oidal 
Neovascularization in the Study Eye and/or Fellow Eye  
Section  9.15 Ocular Imaging  
Text corrected as follows:  
 
The treatment method (pars plana vitrectomy vs  intravitreal injection of 
antibiotics  vitreous tap ) and choice of antimicrobial agents are a lso at the 
discretion of the physician and should follow current standard practice 
patterns .  Section  7.5.3 Endophtha lmitis 
Treatment  
Content in these sections was combined.  Section  7.5.1 Treatment of New 
Active Choroidal 
Neovascularization in the Study E ye 
and/or Fellow Eye  
 
Section  7.5.2 Treatment of 
Neovascular AMD in the Fellow Eye 
References to “biobanking” have been replaced by references to the 
“genetic biorepository” and the “clinical repository” .  Section  8. STUDY DESIGN  
Section  9.7 Genotyping Sa mples  
Section  9.17 Blood Volume for 
Study Assessments  
Protocol updated to specify that microperimetry should be conducted on 
both eyes.  Section  8 STUDY DESIGN  
Noted that blood draws will be conducted for genotyping.  Section  8.1.3.2 Months 13 -24 
Noted th at OCT -A may be conducted, if applicable as per instructions of 
the protocol.  Section  9.6 Laboratory Analysis of 
Blood and Urine  
Text was modified to clarify that t he study staff performing visual acuity Section  9.11 Best-corrected  Visual 
 
 
Apellis Pharmaceuticals, Inc
Page 148 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
should be masked to the treatment assignment  only; the protocol 
previously stated that staff should also be blinded to the study eye . Acuity and Low Luminance Best -
corrected Visual Acuity  
Blood volume for genetic biorepository was updated.  Section  9.17 Blood Volum e for 
Study Assessments  
The following samples were removed:  
• All residual serum and whole blood samples 
collected during the course of the study for PK 
analysis, genotyping and anti APL 2 antibody 
formation  
• Residual serum PK sample  
• Residual serum Anti Therapeut ic Antibodies 
(ATA) sample  
 
It was noted that the 15 mL whole blood sample will be collected at 
Month 2 , baseline , Month 12 and Month 24 of the study  Section  9.18.2 Sample Collection  
It was clarified that the DMC will meet at the beginning of the study an d 
every 6 months thereafter.  Section  10.1 Data Monitoring 
Committee  
Reference to “possibly related” AEs was removed as there is no 
“possibly related” AE categorization for this study.  
 
Resolution outcome possibilities were updated to accurately align with the SAE report forms that will be used for this study.  Section  11.2 Recording Adverse 
Events  
 Section  11.4.1 Relationship of 
Events to Study Treatment  
Clarified that:  
All SAEs will be reported to the Safety Monitor by the Investigator via 
fax or email wi thin one working calendar  day of becoming aware of the 
event, whether or not the serious events are deemed drug -related.  Section  11.5 Serious Adverse Events  
Section reo rganized, modified, and updated to depict protocol 
specifications for data management and statistical considerations more clearly, accurately, and thoroughly.  Section  12. DATA MANAGEMENT 
AND STATISTICAL CONSIDERATIONS  
Footnote was updated to indicate that : All assessments should be 
performed on the same day , with the exception of screening . 
 The blood draw for the clinical repository was removed at baseline, 
Month 1, Month 8, Month 18, and Month 27.  
 
OCT -A was added at screening, Month 6, Month 12, Month 18, and 
Month 24 for select sites . Footnote “R” was added to note that i n 
addition to the time points indicated on the study schedule, OCT -A 
should be performed at the time of any suspected new active CNV . If 
new active CNV is confirmed in the study eye, OCT -A should be 
repeated every 2 months for the study eye . All Study Schedules (Appendice s: 
A, B, C, and D)  
 
 
Apellis Pharmaceuticals, Inc
Page 149 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
APPENDIX K: PROTOCOL CHANGES TO BE FOLLOWED DURING 
COVID- 19 RESTRICTIONS  
OVERVIEW   
In response to the COVID-19 crisis, to ensure the safety of study subjects and Investigative Sites 
as well as proper conduct of the study, TEMPORARY changes to the protocol have been 
implemented . These changes should be followed only during COVID-19 restrictions and include 
extended IP administration windows, changes to masking rules, rescreening instructions, and a revised schedule of assessments .  
Where feasible,  sites could continue to follow the full schedule of assessments (based on their 
treatment group assignment). 
EXTENDED IP ADMINISTRATION WINDOWS  
In order to allow more flexibility to sites and subjects, and to potentially mitigate missed IP admin istration, an extended IP administration window can be followed. Th e extended window 
can ONLY be used in situations related to COVID- 19 restrictions and after medical monitor 
approval. Footnote “T” of each COVID -19 assessment table below reflects these ext ended IP 
options. 
Per protocol, the study window is as followed: 
• Monthly treatment group: +/ –8 days for the entire study duration 
• EOM treatment  group: +/ –8 days for the first study year and +/–16 days for the 
second study year 
During COVID- 19 restrictions, the IP administration  window can be extended to the following: 
• Monthly treatment group: –8 days to +15 days. Note, interval for consecutives 
injection must be at least 14 days.  
• EOM treatment group: –8 days to +30 days for the first study year and –16 days to +30 days for the second study year 
MASKING RULES  
Due to current COVID- 19 restrictions, clinical sites might encounter difficulties maintaining 
appropriate clinic staffing to satisfy the approved masking rules for the APL2-304 ( Oaks ) study. 
Based on thi s, and in an attempt to minimize the amount of missed data and IP administrations, 
Apellis is implementing a  temporary  adjustment to the study masking rules.  
This temporary change must be approved by the Apellis Medical Director prior to  
implementation an d must be documented via a temporary and modified Delegation of Authority 
Log. Each masked assessment performed by an unmasked staff and vice versa (even with Apellis 
approval and following the below guidelines) should be documented.  
The principal investigator (PI) is responsible for the overall safety oversight of the study site data 
and s/he will not be allowed to switch into an unmasked role. Every masked individual that 
performs IP administration and/or post injection  assessment (all unmasked assessment ) as a 
temporary measure, will permanently  be considered an  unmasked individual and will not be 
able to perform masked  assessments once these exemptions are lifted . 
 
 
Apellis Pharmaceuticals, Inc
Page 150 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
RESCREENING PROCEDURE  
Prior to the implementation of these temporary changes, sites continuing to screen patients have 
been encouraged to complete the screening and baseline assessments in their entirety . However, 
if a subject was deemed a screen failure for not being able to meet the original screening window 
(Day –28 to Day –1 [+/–2 days]) due to COVID -19 related restrictions, a rescreening visit is 
allowed and should be followed according to the 2 scenarios below .  
Subjects Who  Completed Screening and Were Considered Eligible by Reading Center and 
Investigator  
Subjects who  were screened prior  to 30 March  2020 and completed  all screening assessments (as 
described in the Schedule of Assessments Appendix A [every month treatment group] and 
Appendix C  [every -other-month [EOM] treatment gr oup]) and considered eligible by the reading 
center and investigator and are able to return to the clinic within 90 days of initial screening, will 
receive a new subject ID number and undergo an abbreviated screening, prior to randomization, 
that includes the following assessments:   
• Informed consent/Assign new screening number  
• NL-BCVA  assessment   
• Slitlamp  examination   
• Dilated indirect ophthalmoscopy  
• IOP measurement   
• SD-OCT*    
• Concomitant medication/concomitant ocular procedures collection   
• AE collection   
*SD-OCT images collected at this visit will not be used by the reading center to determine 
eligibility but should be used by the investigator to detect any potential new exclusion criterion.  
If the investigator deems it necessary, additional assessments can be performed  if there is a 
concern that the subject might now meet an exclusion criterion that was not the case during the original screening (eg, fundus fluorescein angiography to exclude the presence of CNV). 
 
Subjec ts With Incomplete Screening Assessment   
Subjects that signed the informed consent but were not able to complete all screening assessments due to COVID-19- related restrictions  are not eligible for the abbreviated screening. 
These subjects  can be rescreened  but must follow the standard screening schedule of 
assessment  (as described in  the Schedule of Assessments Appendix A  [every month treatment 
group] and Appendix C  [EOM  treatment group]). These subjects will also receive a new 
screening ID number.  
MINIMUM SCHEDULE OF ASSESSMENT  
Schedule of Assessments   
Where feasible,  sites could continue to follow the full schedule of assessments (based on their 
treatment group assignment). The  minimum assessment tables,  only to be followed during this 
 
 
Apellis Pharmaceuticals, Inc
Page 151 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
COVID- 19 effort  and if determined necessary to use based on the investigator’s clinical 
judgment, are provided below to reduce the time required for each study visit. Subjects  in the 
EOM treatment group do not need to be seen for the non- IP administration visits . Assessments 
not performed (even those that have been removed in the minimum assessment table) should be 
documented.  
Subjects that are not able to come into the clinic for a study visit due to COVID-19- related 
restrictions, including visits for the EOM group that do not include IP administration, should 
be contacted via the phone for the collection of adverse events (including SAEs) and 
concomitant medications . All SAEs are still required to be reported to Apellis within 24 
hours  of site awar eness, even if reported via phone call . All communications via phone call 
should also be documented in the source documentation and in the respective CRF page. In 
addition, these subjects should be instructed to self-monitor their vision at home and report any changes in vision or their overall health via phone call. The site must inform the Sponsor of any subjects lost to follow -up. 
 
It is critical that local,  country, and regional governance regarding COVID-19 is followed along 
with your best clinical jud gment when managing this situation. All visits or assessments missed 
as a result of COVID -19 will be captured in the Case Report Forms.  
The Schedule of Assessments tables shown below supers ede those sent on 30 March  2020. These 
changes were previously communicated to the sites via a memorandum.  
 
 
 
Apellis Pharmaceuticals, Inc
Page 152 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
J. Perform assessments prior to dilating the eyes .  
K. In select countries, the MNREAD or Radner Reading Charts should be done during the study visit, prior to dilating the eyes . It should be performed monocularly first, then 
binocularly .  
L. Microperimetry assessments will be performed post  dilation . Data will be forwarded to the reading center .  
M. To be administered by the masked site staff prior to any other assessments performed on that day . In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to  dilating the eyes .  
N. At select sites,  and for  those subjects who decide to participate,  the digital applications will be completed on an electronic device and will consist of assessments for visual 
function and reading speed. Subjects will receive train ing at  Day 1 on the use of the digital applicati ons and the electronic device and will perform the tests using the 
application  in the clinic at Month 1, Month 2, Month 3,  Month 6, Month 12, Month 18, and Month  24. Beginning at  Day 1, subjects will complete  the functional assessments 
weekly at home. Subjects should be instructed to complete the assessments on the same day each week and at approximately the same time of day each week, if possible .  
O. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be p erformed for the study eye only on days where 'SE' is specified 
and for both eyes at all other visits as specified in the above schedule and will be s ent to the reading center for evaluation (consult the reading center manual for specifics on 
image capture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit . If new active CNV is suspected, SD -OCT, FFA and OCT -A (select sites) images 
must be collected and sent to the r eading center for analysis .  
P. Posti njection assessments should be performed within 5 minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable) . If subject passes gross v ision test, the subject may leave the site. If subject fails gross vision test, the tonometry 
should be pe rformed . IOP should be  ≤30 mm  Hg in order for the subject to leave the site . If necessary, anti glaucomatous  medication can be given to lower the IOP . If IOP is  
>30 mm Hg, assessments will continue every approximately 3 0 minutes from the previous measuremen t until the subject passes gross vision test and IOP is ≤3 0 mm Hg. Note: if 
the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham ), the treatment with ranibizumab or 
aflibercept must be performed first . The pre - and  post- anti-VEGF IOP values must be measured and recorded on the eCRF .  
Q. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 3) to collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as  soon as possible .  
R. Record concomitant medications ( ie, prescription and over -the-counter medications) us ed by the patient within 30 days of screening and throughout the subject's participation in 
the study .  
S. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of any suspected new active CNV . If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye .  
T. Administration of pegcetacoplan  or sham  can be don e on separate days from the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If this occ urs on the randomization visit, then the 
administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the m edical monitor . When study treatment administration is on 
a day other than   a study visit, then the only assessment that must be done on the day of study treatment administration is pre injection  IOP. During the COVID -19 pandemic, the 
following flexibility is allowed for IP administration: – 8 days to + 15 days  after medical monitor approval . Note, interva l for consecutive injections must be at least 14 days.  
 
 
Apellis Pharmaceuticals, Inc
Page 155 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
J. Perform assessments prior to dilating the eyes .  
K. In select countries, the MNREAD or Radner Reading Charts should be done during the study visit, prior to dilating t he eyes . It should be performed monocularly first, then 
binocularly .  
L. Microperimetry assessments will be performed post  dilation . Data will be forwarded to the reading center .  
M. To be administered by the masked site staff prior to any other assessments performed on that da y. In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating the eyes.  
N. At select sites,  and for those subjects who decide  to participate,  the digital applications will be completed on an electronic device and will consist of assessments for visual 
function and reading speed. Subjects will receive training at Day1  on the use of the digital applications and the electronic devi ce and will perform the tests us ing the 
application  in the clinic at Month 1, Month 2, Month 3,  Month 6, Month 12, Month 18, and Month  24. Beginning at  Day 1, subjects will complete the functional assessments 
weekly at home. Subjects should be instructed t o complete the assessments on the same day each week and at approximately the same time of day each week, if possible.  
O. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is 
specified   and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for 
specifics on image capture, processing, and transmis sion) . Images should be captured  prior to dosing on dosing days . If a subject misses a study visit or images cannot be 
obtained at a specific visit, study staff should make every effort to obtain images at the next scheduled visit . If new active CNV is sus pected, SD -OCT, FFA, and OCT -A 
(selected sites) images should be collected and sent to the reading center for analysis .  
P. Postinjection assessments should be performed within 5 minutes after dosing by the unmasked physician or study staff and should incl ude a gross assessment of vision  (finger-
counting, hand motion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry 
should be performed . IOP should b e ≤30 mm Hg in order for  the subject to leave the site . If necessary, anti glaucomatous  medication can be given to lower the IOP . If IOP is 
>30 mm Hg, assessments will continue every approximately 3 0 minutes from the previous measurement until the subject p asses gross vision test and IOP is ≤3 0 mm Hg. Note: if 
the study eye is treated with a ranibizumab  or aflibercept  injection during the same visit as the study treatment ( pegcetacoplan or sham ), the treatment with ranibizumab  or 
aflibercept  must be  performe d first . The pre - and  post- anti-VEGF IOP values must be measured and recorded on the eCRF .  
Q. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 3) t o collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as pos sible .  
R. Record concomitant medications ( ie, prescription and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in 
the study .  
S. In addition to the time points indicated on the study schedule , OCT -A should be performed at the time of any suspected new active CNV . If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye .  
T. Administration of pegcetacoplan  or sham  can be done on se parate days fr om the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If this occurs on the randomizat ion visit, then the 
administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the m edical monitor . When study treatment administration is on 
a day other than   a study visit, then the only as sessment that must be done on the day of study treatment administration is pre injection  IOP. During the COVID -19 pandemic, the 
following flexibility is allowed for IP administration: – 8 days to + 15 days  after medical monitor approval . Note, interval for consecutive inj ections must be at least 14 days.  
 
 
Apellis Pharmaceuticals, Inc
Page 158 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
K. In select countries, the MNREAD or Radner Reading Charts should be done during the study visit, prior to dilating t he eyes . It should be performed monocularly first, then 
binocularly .  
L. Microperimetry assessments will be performed post  dilation . Data will be forwarded to the reading center .  
M. To be administered by the masked site staff  prior to any other assessments performed on that day . In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating the eyes.  
N. At select sites,  and for those  subjects who decide to partic ipate,  the digital application will be completed on an electronic device and will consist of assessments for visual 
function and reading speed. Subjects will receive training at Day 1 on the use of the digital applications and  the electronic device and will perform the tests using the in the clinic 
at Month 1, Month 2, Month 3,  Month 6, Month 12, Month  18, and Month 24. Beginning at Day  1, subjects will complete the functional assessments weekly at home. Subjects 
should be inst ructed to complete the assessments on the same day each week and at approximately the same time of day each week, if possible.  
O. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is 
specified   and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for 
specifics on image capture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be 
obtained at a specific visit, study staff should make every effort to obtain images at  the next scheduled visit . If new active CNV is suspected, SD -OCT, FFA, and OCT -A 
(selected sites) images should be collected and sent to the reading center for analysis .  
P. Postinjection assessments should be performed within 5 minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gross vision te st, the tonometry 
should be performed . IOP should be  ≤30 mm Hg  in order for the subject to leave the site. If necessary, antiglaucomatous medication can be given to lower the IOP. If IOP i s 
>30 mm Hg, assessments will continue every approximately 30 minutes from the previous measurement until the s ubject passes gross vision test and IOP is ≤3 0 mm Hg. Note: if 
the study eye is treated with a ranibizumab  or aflibercept  injection during the same visit as the study treatment ( pegcetacoplan or sham), the treatment with ranibizumab  or 
aflibercept  must be performed first . The pre - and  post- anti-VEGF IOP values must be measured and recorded on the eCRF .  
Q. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 4) to collect  any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as poss ible.  
R. Record concomitant medications ( ie, prescription and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in 
the study .  
S. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of any suspected new active CNV . If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye .  
T. Administration of pegcetacoplan  or sham  can be done on separate  days from the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visi t if both days fall within the visit window . If this occurs on the ra ndomization visit, then the 
administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the m edical monitor . When study treatment adminis tration is on 
a day other than a study visit, then the only assessment that must be done on the day of study treatment administration is pre injection  IOP. During the COVID -19 pandemic, the 
following flexibility is allowed for IP administration: – 8 days to + 30 days  after medical monitor approval . 
 
 
 
Apellis Pharmaceuticals, Inc
Page 161 of 164
Confidential
Pegcetacoplan  
APL2 -304 Protocol Amendment 5 12 August 202 0 
K. In select countries, the MNREAD or Radner Reading  Charts should be done during the study visit, prior to dilating the eyes . It should be performed monocularly first, then 
binocularly .  
L. Microperimetry assessments will be performed post  dilation . Data will be forwarded to the reading center .  
M. To be administered by the masked site staff prior to any other assessments performed on that day . In-clinic assessments on t he digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating t he eyes .  
N. At se lect sites,  and for those subjects who decide to participate,  the digital applications  will be completed on an electronic device and will  consist of assessments for visual 
function and reading speed. Subjects will receive training at Day 1 on the use of the  digital applications and  the electronic device and  will perform the tests using the 
application  in the c linic at Month 1, Month 2, Month 3,  Month 6, Month 12, Month 18, and Month  24. Beginning at  Day 1, subjects will complete the functi onal assessments 
weekly at home. Subjects should be instructed to complete the assessments on the same day each week and at approximately the same time of day each week, if possible.  
O. FAF and SD -OCT images, near infrared reflectance, fluorescein angiogr ams, and fundus photographs will be performed for the study eye only on days where 'SE' is 
specified   and for both eyes a t all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center  manual for 
specifics on image capture, processing, and transmission) . Images should be captured prior to dosing on dosin g days . If a subject misses a study visit or images cannot be 
obtained at a specific visit, study staff should make every effort to obtain images at the next scheduled visit . If new active CNV is suspected, SD-OCT,  FFA,  and OCT -A 
(selected sites)  images sh ould be collected and sent to the reading center for analysis .  
P. Postinjection assessments should be performed within 5 minutes after  dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand m otion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gr oss vision test, 
the tonometry  should be performed. IOP should be ≤3 0 mm Hg in order for the subject to leave the site. If necessary, antiglaucomatous medication can be given to lower the 
IOP. If IOP is > 30 mm Hg, assessments will continue every approximately 3 0 minutes from the previous measurement until the subject passes the gross vision test and IOP is 
≤30 mm Hg. Note: if the study eye is treated with a ranibizumab  or aflibercept  injection during the same visit as the study treatment (pegcetacoplan  or sham), the treatment with 
ranibizumab  or aflibercept  must be performed first . The pre - and post - anti-VEGF IOP valu es must be measured and recorded on the eCRF .  
Q. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days af ter each study treatment visit (through Month  4) to collect any information on any 
safety concerns, decrease in vi sion, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the  investigator  determines that there are any safety 
concerns, a follow -up visit should be scheduled as soon as possible .  
R. Record concomitant medications ( ie, prescr iption and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in 
the stu dy.  
S. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of a ny suspected new active CNV . If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye .  
T. Administration of pegcetacoplan  or sham  can be done on separate days from the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if bo th days fall within the visit window . If this occurs on the randomization visit, then the 
administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the m edical monitor . When study treatment administration  is on 
a day other than   a study visit , then the only assessment that must be done on the day of study treatment administration is pre injection  IOP. During the COVID -19 pandemic, the 
following flexibility is allowed for IP administration: – 16 days to + 30 days after medical monitor approval . 
 
 
 
Apellis Pharmaceuticals, Inc
Page 164 of 164
Confidential